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ABSTRACT: We report the design, synthesis, and biological evaluation of
some potent small-molecule neuropilin-1 (NRP1) antagonists. NRP1 is
implicated in the immune response to tumors, particularly in Treg cell fragility,
required for PD1 checkpoint blockade. The design of these compounds was
based on a previously identiﬁed compound EG00229. The design of these
molecules was informed and supported by X-ray crystal structures. Compound
1 (EG01377) was identiﬁed as having properties suitable for further
investigation. Compound 1 was then tested in several in vitro assays and
was shown to have antiangiogenic, antimigratory, and antitumor eﬀects.
Remarkably, 1 was shown to be selective for NRP1 over the closely related
protein NRP2. In puriﬁed Nrp1+, FoxP3+, and CD25+ populations of Tregs
from mice, 1 was able to block a glioma-conditioned medium-induced increase
in TGFβ production. This comprehensive characterization of a small-molecule
NRP1 antagonist provides the basis for future in vivo studies.
■ INTRODUCTION
Neuropilin- 1 (NRP1) is a cell-surface coreceptor for a number
of diﬀerent growths factors, including several diﬀerent isoforms
of vascular endothelial growth factor (VEGF), transforming
growth factor-β1 (TGF-β1), PLGF, HGF (also known as
scatter factor) as well as Semaphorins 3A, 4F.1 As such, NRP1
plays key roles in both vascular and neuronal development.2,3 It
has also been shown that NRP1 has an important
immunological function.4 NRP1 is expressed on several types
of immune cells, including T cells and dendritic cells, where it is
one of the components of the immunological synapse.5 NRP1
is implicated in potentiating the function and survival of
regulatory T cells (Tregs).6 This T cell fragility is linked to
responses to PD1 checkpoint inhibitors.7 NRP1 expression can
be used to distinguish Treg subsets arising in vivo, thus NRP1
is present on thymus derived Tregs (natural Tregs),8 whereas it
is not present on Foxp3+ positive inducible Tregs.9,10 The
Ikaros family protein Helios has been suggested as an additional
and more general marker for thymic derived Tregs.11
NRP1 is also important in the control of the M2 shift in
tumor associated macrophages/microglia in gliomas.12 NRP1
interacts with TGFβR1 to activate SMAD2/3 and drive
secretion of TGF-β1, which results in expansion of Treg
subsequent immune suppression.13−15 As the role of the
immune system in cancer development becomes better
understood,16 NRP1 is emerging as an attractive anticancer
target.17 Novel drug compounds which act as NRP1 antagonists
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could therefore exhibit their anticancer eﬀects in three diﬀerent
ways: blocking tumor angiogenesis by blocking the NRP1/
VEGF-A interaction,18 preventing tumor cell migration by
binding to NRP1,19 and reducing Treg or macrophage
mediated suppression of the immune response.20
A number of peptide antagonists of neuropilin are known:
ATWLPPR21 is a low aﬃnity linear peptide, whereas a bicyclic
disulﬁde bonded peptide, EG3287, is derived from the C-
terminal domain of VEGF-A22 (Scheme 1). N-Terminal
modiﬁcation (N-octanoyl) resulted in a high aﬃnity antagonist
EG00086 (KD = 76 nM).
23 EG00086 was also shown to inhibit
VEGF-A mediated cell signaling, including cell adhesion,
through reduction in p130Cas tyrosine phosphorylation. Its
usefulness for in vivo studies was limited, however, by its low
plasma stability (t1/2 < 5 min).23 In addition, NRP1
antibodies18 and a mini-protein based on the kalata cyclotide
have been reported.24
Development of a potent, small molecule NRP1 antagonist,
with increased in vivo stability, would therefore be attractive.
Despite the interest in this area, only a small number of
molecules have been identiﬁed25−27 These molecules are
reported to have micromolar potencies, and some antitumor
eﬀects have been claimed in vivo. The best characterized of
these is (S)-2-(3-(benzo[c][1,2,5]thiadiazole-4-sulfonamido)-
thiophene-2-carboxamido)-5-((diaminomethylene)amino)-
pentanoic acid (EG00229), which has been previously
identiﬁed as a speciﬁc inhibitor of the NRP1/VEGF-A
interaction.27 Other compounds, such as the benzimidazole-
based inhibitor exempliﬁed by N-((5-(1H-benzo[d]imidazol-2-
yl)-2-methylphenyl)carbamothioyl)-2,3-dihydrobenzo[b][1,4]-
dioxine-6-carboxamide were identiﬁed through screening
approaches (Scheme 1).25 EG00229 was shown to inhibit the
binding of biotinylated VEGFA (bt-VEGF-A) to NRP1 with an
IC50 of 8 μM. It was also demonstrated to have functional
eﬀects on cell-migration and VEGF-R2 phosphorylation.27
Further studies have shown EG00229 to reverse an immune
phenotype elicited by the immunomodulatory peptide tuftsin
by blocking canonical TGFβ signaling through SMAD3/
AKT.28 When delivered locally, the compound also inhibits
glioma proliferation in vivo, replicating genetic ablation
studies.12 In squamous cell carcinoma, the compound
suppresses epidermal stem cell function and tumor formation
in vivo.29 The binding mode of EG00229 has been conﬁrmed
by NMR and crystallographic studies, providing a useful
starting point for the development of new NRP1 antagonists.27
Herein, we utilize EG00229 as a starting point for the discovery
of potent and bioavailable inhibitors of the NRP1/VEGF-A
interaction, resulting in the identiﬁcation of 1 (EG013777) as a
new lead.
■ RESULTS AND DISCUSSION
Structure-Based Design of New NRP1 Antagonists.
The crystal structure of EG00229 bound to human NRP1-b1
was previously solved to 2.9 Å resolution (PDB 3I97), and two
diﬀerent binding poses for the ligand were identiﬁed (Figure
1A,1B).27 The crystal structure revealed a close ﬁt of the
arginine portion of the molecule into the NRP1 binding pocket
with near identical conformations observed for this part of the
molecule. As previously noted, the 3-aminothiophene-2-
carboxylic acid displays an H-bonded constrained conformation
in the bound molecule, indicating the presence of an alternate
tautomeric form of this substructure. In contrast, the positions
of the benzothiadiazole group were markedly diﬀerent.
Although the two binding poses of EG00229 were distinct,
the positions of the protein side chains were identical when
overlapping the two chains, except for E348. We hypothesized
that through further modiﬁcation and elaboration of the
EG00229 scaﬀold, more potent NRP1 antagonists could be
synthesized. Using chain B as an illustration (Figure 1B), two
key amino acids were identiﬁed which could be targeted either
to improve existing H-bond interactions (S298) or to introduce
new ones (E348).27
Scheme 1. Previously Identiﬁed Small Molecule and Peptidic Antagonists of NRP1
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Chemistry. To target outer pocket residues, such as S298
and E348, a range of substituted dihydrobenzofurans were
prepared. These were designed to be able to make potential
hydrogen bonding or salt bridge contacts with the S298 and
E348 residues. The ﬁrst part of the general synthetic route for
the 5-substituted dihydrobenzofuran series is shown (Scheme
2). The synthesis began with sulfonamide formation between 5-
bromo-2,3-dihydrobenzofuran-7-sulfonyl chloride 2 and methyl
3-aminothiophene-2-carboxylate, to give sulfonamide 3.
Hydrolysis of the methyl ester with LiOH gave acid 4, which
was then coupled with the Pbf-protected arginine methyl ester
to give 5. Subsequent hydrolysis of 5 gave the key intermediate
6, which was suitable for Suzuki−Miyaura couplings with a
range of arylboronic acids.
From this common brominated intermediate 6, a range of
azaheterocycles were prepared as shown in (Scheme 3). First,
intermediate 6 was coupled to either 2- or 3-formylphenyl
boronic acid to give 7a,b, and then reductive aminations were
carried out using the desired amine to furnish substituted
analogues 8 (for deﬁnitions of R, see Tables 1−3). Removal of
the Pbf-protecting group in acidic conditions gave the ﬁnal
products 9a−e, 10a−e (Table 1), 11a−e, 12a−e, and 13a
(Table 2).
The synthesis of primary methylaminoaryl analogues was
achieved by the use of preformed boronic acids (Scheme 4).
Thus, 6 under Suzuki−Miyaura conditions with the 2- or 3-
methylaminoboronic acids gave the intermediates 14a−c,
which with Pbf removal gave the target molecules 15a, 15b,
and 1. For large scale batches of 1, a slightly modiﬁed synthetic
route was employed with a Boc protected methylaminoboronic
Figure 1. Two poses of EG00229 (PDB 3I97): C atoms in magenta
and brown. In (B), a H-bond is formed with S298.
Scheme 2. Synthesis of Brominated Dihydrobenzofuran
Scaﬀolda
aReagents and conditions: (a) methyl 3-aminothiophene-2-carbox-
ylate, pyridine, 0 °C to rt, 20 h; (b) LiOH, THF, MeOH, H2O, 45 °C,
20 h; (c) H-L-Arg(Pbf)-OMe, PyBrop, DIPEA, CH2Cl2, rt, 18 h; (d)
LiOH·H2O, THF, H2O, rt, 3 h.
Scheme 3. Synthesis of Aryl Substituted
Dihydrobenzofuransa
aFor deﬁnitions of R, see Tables 1−3. Reagents and conditions: (a)
Pd(PPh4)Cl2, K2CO3, DME, H2O, 90°; (b) amine, AcOH, then
NaHCNBH3, DMF; (c) DCM, TFA 1:1.
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acid (Supporting Information, Scheme S1). For the synthesis of
cyclized isoindolyl analogues, 6 was transformed into the
functionalized boronic acid 16 using bispinacolato diboron and
Pd(dppf)Cl2, and this was used directly for the Suzuki−
Miyaura coupling using potassium acetate as the base and
Pd(PPh4) as the palladium catalyst (Scheme 5). In this case,
cesium carbonate was preferred as the base. Final deprotection
of the Pbf group furnished the isoindolyl analogues 18a and
18b.
Crystallographic Studies of 1. To further investigate the
binding of 1 to NRP-1, X-ray crystallography studies were
carried out. The diﬀerences in binding modes between 1 and
EG00229 were then analyzed. The structure of 1 bound to
NRP1-b1 was determined in two conformations: a high (0.9 Å)
and a low (2.8 Å) resolution structure (Figure 1). The high-
resolution crystal structure provides us with the most detailed
view of the ligand-binding site to date. The reﬁned model
includes residues 273−427 of NRP1-b1, 39 non-hydrogen
atoms of 1 and 472 water molecules. High resolution allowed
us to observe multiple conformations of the side chains; 24 side
chains were reﬁned with at least two alternative rotamers.
Comparison of NRP1-b1/compound 1 complexes indicate that
the ligand can bind in two diﬀerent conformations. In the low-
resolution 2.8 Å structure (PDB 6FMF), the ligand’s bulky
aromatics extend out of the back of the binding pocket. In the
high resolution 0.9 Å structure (PDB 6FMC), they extend out
of the top of the binding pocket (Figure 2). The diﬀerence in
ligand conformation originates from a rotation about the
carbon−carbon bond axis of the carboxyl group, which forms
hydrogen bonds to S346 and T349. There is an approximate
77° rotation along this bond (Figure 2B and Supporting
Information, Figure S1), resulting in more than 1 Å separation
between the two diﬀerent conformations. By exiting out of the
top of the binding pocket, the ligand in the high-resolution
structure forms additional interactions with the N-terminal
residues (in particular G271−M276) of a symmetry mate
Table 1. Equilibrium Binding Constants for Substituted Azaheterocycles
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00210
J. Med. Chem. 2018, 61, 4135−4154
4138
located above the NRP1-b1 binding pocket. It is likely these
interactions improve the crystal contacts, increasing crystal
order, which is necessary to produce the higher resolution data
explaining the diﬀerence in resolution between the two
conformations. These contacts are however a crystallographic
artifact, with the lower resolution structure more likely to
represent the true conformation of 1 bound to NRP1-b1. The
diﬀerence in ligand conformations results in a signiﬁcant
change in the side chain rotamer of E348. In the low resolution
structure, E348 points away from the binding pocket and forms
a hydrogen bond with the aryl-NH2 of 1, which may help to
explain the compound’s increase in potency. In the high
resolution structure, the aryl-NH2 of 1 does not interact with
E348 changing the side chain rotamer such that it now faces
toward the center of the binding pocket. The detection of the
hydrogen-bond to E348 in the low resolution structure
conﬁrmed our modeling predictions.
Biological Evaluation. All the compounds were evaluated
using an SPR binding assay (Biacore) where recombinant
NRP1-b1b2 protein was immobilized on a dextran coated
chip.23 Selected compounds were then evaluated in competitive
binding assay systems using biotinylated VEGF. As part of an
extensive structure−activity investigation, the binding of 9a and
10a to the NRP1-b1 domain was assessed by SPR and
Table 2. Equilibrium Binding Constants for Substituted Methylpiperidines
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promising activity noted for the morpholine extended analogue
10a with binding aﬃnity of 3.76 ± 0.52 μM by SPR as opposed
to 14.43 ± 3.76 μM for the unsubstituted compound 9a. This
encouraging result prompted us to conduct a more focused
structure−activity study around the 10a structure.
The ﬁrst group of analogues examined heteroaryl sub-
stituents on the 2′ and 3′ positions. All of the synthesized
compounds 9b−e and 10a−e showed binding to the NRP1-b1
domain, with some compounds demonstrating nanomolar KD
values. Substitution at the 3-position seemed generally
favorable, with all of the 3-substituted compounds, 10a−e,
showing higher binding aﬃnities than the 2-substituted
analogues.
A further range of analogues, 11a−e and 12a−e, were
designed which contained a functionalized piperidine linker to
add length and ﬂexibility to further explore outer-pocket
interactions. Binding aﬃnities to the NRP1-b1 domain were
again assessed by SPR (Table 2).
The resulting compounds once again showed binding to
NRP1, although the binding aﬃnities were generally lower than
had been observed for the previous azaheterocyclic compounds.
The highest binding aﬃnity for this series was obtained for the
nonfunctionalized piperidine 12a (KD = 1.17 μM). The
generally lower binding aﬃnities for 11a−e suggested that
the addition of the piperidine linker was not an eﬀective
strategy to introduce speciﬁc interactions with any additional
surface amino acid residues, and so this series was not pursued
further. With these results in hand, a compound set with
smaller methylamino substituents that could be accommodated
at the 4-position was synthesized (Table 3). Compounds 1 and
13a−e showed consistent activity although this declined with
the methylated analogue 13c. Compound 1 showed reasonable
aﬃnity (Figure 3A,B), which was encouragingly maintained in
both cell-based and cell-free competition assays with bt-VEGF
(Table 4). Isothermal calorimetry data for 1 ﬁtted to a one-site
binding model and provided an orthogonal assay system
(Figure 3B). Evaluation of 1 against NRP2, a closely related
receptor to NRP1, showed no detectable binding (Supporting
Information, Figure S2), indicating very good selectivity. These
results prompted us to investigate the pharmacokinetic proﬁles
of some selected analogues.
Pharmacokinetics. Both of the compounds from the
dihydrobenzofuran series exhibited improved PK proﬁles over
the historical compound EG00229, which has a relatively short
half-life of 0.5 h.12 Compound 10d had a longer half-life (1.2 h)
with an improved Vd of 1103 mL/kg (Table 4). Compound 1
also exhibited an encouraging half-life of 4.29 h, suﬃcient to
sustain once per day dosing. The methylated analogue 13c
showed less favorable parameters with a notably higher
clearance and lower AUC than 1. With this data in hand
demonstrating 1 to be a reasonably potent and stable inhibitor,
we undertook a thorough biological characterization of 1
examining its antiangiogenic, antitumor, and immune eﬀects.
Compound 1 Inhibits VEGF-A Stimulated Tyrosine
Phosphorylation of VEGF-R2/KDR. VEGF-A signaling
through VEGF-R2/KDR plays an important role in cell
function in endothelial, tumor, and other cell types.30 We
investigated the eﬀect of 1 on VEGF-R2/KDR tyrosine
phosphorylation induced by VEGF-A in HUVECs. VEGF-A
(1 ng /mL) stimulated a signiﬁcant increase in VEGF-R2/KDR
tyrosine phosphorylation at 10 min, which was inhibited by
50% on treatment with 1 at 30 μM (Figure 4). Studies with 1
had previously shown a 20% inhibition at 30 μM.27 These
results once again indicate the importance of NRP1 for optimal
VEGF function and signaling1 and conﬁrmed the higher
potency of 1 compared to EG00229 as indicated by its higher
aﬃnity for NRP1-b1 and higher potency in a cell-free binding
assay.
Angiogenesis, Inhibition of VEGF-Induced Migration
in HUVEC Cells. To investigate the importance of blocking
Scheme 4. Synthesis of Methylaminoaryl Substituted
Analoguesa
aReagents (a) Pd(PPh4)Cl2, K2CO3, DME, H2O, 90°; (b) DCM, TFA
1:1.
Scheme 5. Synthesis of Isoindoyl Substituted
Dihydrobenzofuransa
aReagents and conditions: (a) bispinacolato diboron, Pd(dppf)2Cl2,
KOAc, dioxane; (b) Pd(PPh4)Cl2, CsCO3, DME, H2O, 90°; (c) DCM,
TFA 1:1.
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NRP-1 in HUVEC cells, we performed transwell assays of
chemotaxis and in vitro scratch assays of wound closure
(chemokinesis). The transwell assay examines cell chemotaxis,
the directional cell migration toward the chemo-attractant. To
understand if 1 could inhibit VEGF-A-induced migration of
HUVEC cells, 2 × 105 HUVEC cells were plated in serum-free
medium (EBM) with the addition of either 0.1% DMSO, 25
ng/mL VEGF-A, 1 (30 μM), or a combination of VEGF-A and
1 on the bottom chamber. Cells were allowed to migrate
through the pores of the insets for 4 h. Data collected was
consistent with previous reports,31 with VEGF-A being able to
induce HUVEC cells migration by almost 3 times more
compared to DMSO control (Figure 5A,B). Treatment of
HUVEC cells with 1 alone did not inﬂuence the migratory
ability of these cells but the administration of 1 at 30 μM in the
presence of VEGF-A signiﬁcantly reduces, by more than 60%,
the ability of cells to migrate toward VEGF-A stimulus (Figure
5B). These results suggest that 1 has a higher potency than the
previously reported compound, EG00229,27 that only displayed
signiﬁcant inhibition (≈34% reduction) once used at 100 μM
in combination with VEGF-A.
Wound Healing Scratch Assay. HUVEC cells were plated
and once conﬂuent a scratch was made as described in the
methods. Cells were kept in culture for 5 days in 1% EGM with
0.1% DMSO, 25 ng/mL VEGF-A, 1 (30 μM), or a combination
of VEGF-A and 1. Data shows that 1 can delay the VEGF-
induced wound closure (Figure 5C).
Compound 1 in Combination with VEGF-A Reduces
Network Area, Length, and Branching Points. Next, we
used an organotypic endothelial−ﬁbroblast coculture assay to
recapitulate the endothelial tube formation characteristic of
VEGF-A stimulated angiogenesis. The coculture assay of
angiogenesis is a simple in vitro assay where HUVEC cells
are cultured with human embryonic ﬁbroblasts (HDF). The
layer of ﬁbroblasts secretes a complex extracellular matrix that
contains collagen I with ﬁbronectin, tenascin-C, decorin, and
versican, mimicking the composition of tissue stroma. This
matrix becomes remodelled into a 3D environment, allowing
HUVECs to reorganize into a network of tubes.
This assay is particularly suited to test factors that promote
or inhibit angiogenesis. Thus, we next analyzed endothelial
tubulogenesis in coculture HUVEC cells treated with either
VEGF-A or VEGF-A + 1 during 4 days (Figure 6). Data
collected shows that HUVEC cells stained for the endothelial
marker Von Willebrand factor (VWF), have a ≈41% reduction
in the number of VEGF-induced branch points in tubular
networks upon NRP1 inhibition with 1 (Figure 6B). This
reduction was also observed when overall network area (≈50%)
and length (≈40%) (Figure 6B) were assessed. Results suggest
that NRP1 inhibition can signiﬁcantly inﬂuence the angiogenic
properties of endothelial cells, thus being an attractive target to
test on highly metastatic cancers that express NRP1.
Reduced VEGF-Induced Angiogenesis after Treat-
ment with 1. To further analyze the eﬀect of blocking
NRP1 during angiogenesis, we next used an ex vivo mouse
aortic rings assay. The aortic ring assay provides a more
complete picture of angiogenic processes compared with
traditional cell-based assays. In this model, endothelial cells
are able to proliferate and migrate, forming network tubes and
branching points without the need for cellular dissociation.32
This allows us to assess diﬀerent steps that occur during the
angiogenic process, which we aim to target. Rings were
Figure 2. Two crystallized forms of 1 with NRP1-b1. (A) Low resolution 2.8 Å structure PDB 6FMF (cyan) shows the H-bond from the
methylamino of 1 to E348. (B) High resolution 0.9 Å PDB 6FMC (green) showing alternate conformation of 1. The conformation of E348 is also
diﬀerent. (C) Overlay of low (cyan) and high (green) resolution structures showing bond rotation around the Cα-COO bond.
Table 3. Equilibrium Binding Constants for Methylamino
Analogues
ID R SPR KD [μM]
13 3′-CH2NMe2 4.52 ± 1.36
15a 2′-CH2NH2 1.87 ± 0.32
15b 3′-CH2NH2 2.44 ± 0.71
1 4′-CH2NH2 1.32 ± 0.08
18a 2′,3′-(CH2NHCH2) 2.47 ± 0.25
18b 3′,4′-(CH2NHCH2) 2.17 ± 0.32
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embedded in collagen and kept in culture in medium
containing 0.1% DMSO, 25 ng/mL VEGF-A, 1 (30 μM), or
a combination of VEGF-A and 1. As expected, after 7 days in
culture, VEGF-A increased vessel sprouting from WT aortic
rings, but this response was signiﬁcantly suppressed (≈7-fold
reduction) by the administration of 30 μM of 1 (Figure 7A,B).
Studies have described that NRP1 up-regulation is associated
with the tumor invasive behavior and metastatic potential, for
instance, in melanoma and breast cancer.17,33 Thus, our data
reinforces the importance of targeting NRP1 and suggest a
possible attractive therapeutic approach for cancers that are so
far resistance to the traditional angiogenic therapies.
Antitumor: Blocking NRP1 Reduces Melanoma In-
vasion in a 3D Spheroid Assay. To further investigate the
eﬀects of NRP1 blockade on cancer cells, we used a three-
dimensional (3D) spheroid assay. 3D spheroids are a useful
tool to replace the commonly used 2D cell culture systems. By
using this system, we aimed to recapitulate how cells grow in
vivo in three dimensions.
NRP1 expression is associated with melanoma progression
and invasiveness. In addition, studies have shown that these
properties can be inhibited by the use of anti NRP1 antibodies
or shRNA constructs.34 Thus, we hypothesize that NRP1 is a
potential target for the treatment of the metastatic melanoma.
In our study, we have used A375P (malignant melanoma) cells
that express NRP1 (data not shown).
A375P spheroids were embedded in collagen and treated
with medium supplemented with 0.1% DMSO, 25 ng/mL
VEGF-A, 1 (30 μM), or a combination of VEGF-A and 1
(Figure 8A). Data collected shows that treatment with 1 in
A375P cells signiﬁcantly inhibited invasion induced by VEGF-
A, whereas 1 treatment on its on its own had no signiﬁcant
eﬀect on radial invasion compared to the DMSO control
(Figure 8B). These results further establish an important role
for blocking NRP1 in regulating VEGF-A mediated signaling,
which are essential for cell motility and invasion in melanoma
cells.
Blocking NRP1 on Regulatory T Cells (Treg) with 1
Reduces Their Production of TGFβ in the Presence of
Glioma-Conditioned Media (GCM). Nrp1 is upregulated on
the surface of Treg and is vital to their maintenance. Nrp1+
Treg populations have also been shown to induce allograft
tolerance and limit potential antitumorigenic responses in
murine models. Depletion of Nrp1+ Treg leads to enhancement
of antitumoral immune responses, making them a favorable
population of cells to target pharmacologically.6,35 To
determine whether 1 had the potential to block the pro-
tumorigenic polarization of Nrp1+ Treg, we isolated and
puriﬁed Nrp1+, FoxP3+, and CD25+ populations of Treg from
mice (Figure 9A) and exposed them to glioma conditioned
media (GCM)12 for 12 h after pretreating the cells with 1.
TGFβ is normally present in GCM36,37 and contributes to the
immunosuppressive tumor microenvironment because interfer-
ence with TGFβ expression has been shown to strongly
promote recognition of glioma cells by cytotoxic T cells and
NK cells.37 Treatment of the Nrp1+ Tregs with GCM alone
activated the Tregs, which resulted in further increased TGFβ
Figure 3. Biophysical binding data supports the interaction of compound 1 with NRP1-b1 protein. (A) Dose response analysis of equilibrium
binding of 1 determined by SPR. (B) Isothermal calorimetry of 1 with NRP1-b1 using 19 consecutive injections of 1 (200 μM stock solution)
applied at 2 min intervals.
Table 4. Cell-Free and Cell-Based Binding Data for
Compound 1
binding assay value
ITC NRP1-b1 (Ka) 4.14 × 10
6 ± 3.84 × 105
cell-free NRP1-a1,b1 (IC50) 0.609 ± 0.066 μM
DU145/cells.Ad.NRP1, IC50 (HS) 1.6 μM (0.9)
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cytokine production, while pretreatment of the cells with 1
inhibited the GCM-induced production of TGFβ (Figure 9B).
■ CONCLUSION
A focused set of novel NRP-1 antagonists were designed using
structure-based drug design to allow targeting of speciﬁc
residues located close to the binding pocket of arginine. X-ray
crystallography was able to conﬁrm that these interactions were
being formed and enabled the design of further analogues.
Compounds were tested in several diﬀerent assays to conﬁrm
binding to NRP1 and inhibition of NRP1−VEGF complex
formation. Of these new inhibitors, compound 1 shows
consistent biological activity and good stability in vivo. It
exhibits submicromolar potency in inhibition of VEGF-A
binding to NRP1 and good functional inhibition of VEGF
driven angiogenesis, cell migration, tumor invasiveness, and
notably Treg cell activation. The compound also demonstrates
a sustained IV PK proﬁle, making it an exciting new proof-of-
concept molecule for the investigation of NRP-1 antagonists as
anticancer therapies (Table 5).
■ EXPERIMENTAL SECTION
Materials and Methods. Chemistry. All materials were obtained
from commercial suppliers and used without further puriﬁcation unless
otherwise noted. Anhydrous solvents were either obtained from
Aldrich or Fisher Scientiﬁc and used directly. All reactions involving
air- or moisture-sensitive reagents were performed under a nitrogen
atmosphere. Routine analytical thin layer chromatography was
performed on precoated plates (Alugram, SILG/UV254). Reaction
analyses and purity were determined by reverse-phase LC-MS using an
analytical C18 column (Phenomenex Luna C18 (2) 50 mm × 4.6 mm,
5 μm for 4.5 and 13 min methods), using a diode array detector and an
A:B gradient starting from 95% A:5% B at a ﬂow rate of 2.25 mL/min
or 1.5 mL/min, where eluent A was 0.1% formic acid/H2O and eluent
B was 0.1% formic acid/MeOH or eluent A was 10 mM NH4HCO3
(aq) and eluent B was MeOH. Silica gel chromatography was
performed with prepacked silica gel Biotage SNAP (KP-Sil) cartridges.
Ion exchange chromatography was performed using Isolute Flash
Figure 4. Compound 1 inhibits VEGF-A stimulated tyrosine
phosphorylation of VEGF-R2/KDR. HUVECs were grown to
conﬂuence and serum-starved with medium containing 0.5% serum
for 16 h. Cells were preincubated for 30 min with medium containing
0.1% DMSO (Veh) 3, 10, and 30 μM 1 or medium alone followed by
stimulation with 1 ng mL−1 VEGF-A or with no further treatment
(control) for 10 min. Cell lysates were then prepared, blotted, and
probed with the indicated antibodies. The data shown are
representative of three independent experiments. Quantitation of
pVEGF-R2/KDR phosphorylation was performed by densitometry
using ImageJ; see Materials and Methods. Data are presented as
pVEGF-R2/KDR phosphorylation relative units (RU; means ± SEM)
normalized to total VEGF-R2/KDR; p < 0.05 = * and p < 0.001 =
***.
Figure 5. Compound 1 is able to signiﬁcantly reduce HUVEC cell
migration in response to VEGFA. (A) 8× magniﬁed images
representing HUVEC cells (stained in blue) that migrate through
membrane pores toward serum free medium supplemented with 0.1%
DMSO as vehicle control (Veh), VEGF 25 ng/mL, 1 (30 μM), and 1
(30uM) + VEGF 25 ng/mL. (B) Graphical representation. Data
represent the average number of migrated cells of ﬁve independent
experiments ± SEM; ***P ≤ 0.001. (C) HUVEC cells were starved
overnight in 1% EBM before a precise scratch was generated using the
WoundMaker (Essen BioScience). Migration was assessed in the
presence or absence of medium containing 0.1%DMSO (Veh), VEGF
25 ng/mL, 1 (30 μM), and 1 (30 μM) + VEGF 25 ng/mL, using an
IncuCyte ZOOM live-cell imaging platform. The graph represents
three independent experiments: means ± SEM. Each treatment per
experiment was performed in 12 replicates.
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SCX-2 cartridges. Reverse-phase preparative HPLC was carried out on
a Waters ZQ instrument using mass-directed puriﬁcation on a
preparative C18 column (Phenomenex Luna C18 (2), 100 mm ×
21.2 mm, 5 μm). Depending upon the retention time and the degree
of separation of the desired compound from any impurities, an A:B
gradient was employed starting from high %A/low %B at a ﬂow rate of
20 mL/min. The following combinations of A and B were typically
used: A = H2O + 0.1% formic acid and B = MeOH + 0.1% formic acid,
or A = 10 mM NH4HCO3 (aq) and B = methanol.
1H and 13C spectra
were measured with Bruker NMR spectrometers as indicated. All
observed protons are reported as parts per million (ppm) and are
aligned to the residual solvent peak, e.g., for DMSO-d6 at δH 2.50 and
δC 39.5 and for CDCl3 at δH 7.26. Data are reported as follows:
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, br =
broad, m = multiplet), coupling constants (J) recorded in Hz, and a
number of protons. Low-resolution mass spectrometry data were
determined on Waters ZQ4000 single quadrupole, Micromass Ultima
triple quadruple mass spectrometers or Agilent 6100 single quadru-
pole/1200 series. High-resolution mass spectroetry was determined
using an Orbitrap. All compounds tested (bioassays) were determined
to be at least 95% pure by LC-MS unless otherwise stated.
Compound Synthesis and Characterization. (3-((5-(4-
(Aminomethyl)phenyl)-2,3-dihydrobenzofuran)-7-sulfonamido)-
thiophene-2-carbonyl)-L-arginine (1). The standard method for
Suzuki coupling was used with (4-(aminomethyl)phenyl)boronic
acid (1.5 equiv), 6 × 0.62 scale reactions. Combined reactions
puriﬁed to give 14c as a white solid, 534 mg, 0.64 mmol, 35%. LC-MS
Rt 2.29 min. MS m/z −839 [M + 1]+. Pbf protecting group was
removed using the standard procedure to give a white solid, 164 mg,
0.55 mmol, 44%. HRMS (ES +ve): Calculated for C26H31N6O6S2
587.1746, Measured mass: 587.1745. 1H NMR (700 MHz, 19 mg in
DMSO-d6,0.5 mL, plus 50 μL of D2O) δ 7.79 (s, 1H), 7.67 (s, 1H),
7.65−7.60 (m, 3H), 7.50 (d, J = 7.7 Hz, 2H), 7.18 (d, J = 5.5 Hz, 1H),
4.64 (t, J = 8.8 Hz, 2H), 4.34−4.29 (m, 1H), 4.04 (s, 2H), 3.30−3.19
(m, 2H), 3.10 (t, J = 7.1 Hz, 2H), 1.88−1.81 (m, 1H), 1.78−1.70 (m,
1H), 1.58−1.46 (m, 2H). 13C NMR (176 MHz, DMSO-d6 plus 50 μL
of D2O) δ 172.93, 158.58, 158.38, 156.22, 141.03, 138.74, 132.75,
132.01, 131.98, 130.15, 129.61, 128.98, 126.56, 124.53, 119.95, 115.25,
113.27, 73.76, 51.90, 41.66, 40.12, 28.25, 27.13, 25.37.
3-(5-Bromo-2,3-dihydro-benzofuran-7-sulfonylamino)-thio-
phene-2-carboxylic Acid Methyl Ester (3). To a stirred solution of 5-
bromo-2,3-dihydro-benzofuran-7-sulfonyl chloride (1.25 equiv, 13.6 g,
47.6 mmol) in pyridine (anhydrous, 50 mL) under nitrogen (balloon),
at 20 °C, was added dropwise over 2 h a solution of methyl-3-
aminothiophene-2-carboxylate (1 equiv, 6 g, 38.1 mmol) in pyridine
(anhydrous, 10 mL). The resulting suspension was stirred at 20 °C for
18 h, and after this time the reaction mixture was cooled (approx 0
°C) and water (50 mL) added dropwise. Precipitation occurred and
the mixture was further diluted with water (100 mL) and the desired
product collected by ﬁltration, washed with ice-cold water (2 × 50
mL), and dried in vacuo to aﬀord 3. Yield: 15.6 g, 37.4 mmol, 98%.
Oﬀ-white solid. LC-MS: tR = 4.42 min. MS: m/z 416/418 [M − 1]−.
HRMS: Calculated for C14H13BrNO5S2 417.9419. Measured mass:
417.9428. 1H NMR (600 MHz, DMSO-d6) δ 9.88 (s, 1H), 7.86 (d, J =
5.5 Hz, 1H), 7.71−7.67 (m, 1H), 7.63−7.59 (m, 1H), 7.22 (d, J = 5.5
Hz, 1H), 4.67 (t, J = 8.8 Hz, 2H), 3.82 (s, 3H), 3.27−3.20 (m, 2H).
13C NMR (151 MHz, DMSO-d6) δ 163.24, 155.98, 141.86, 134.12,
133.88, 133.53, 128.23, 121.05, 120.39, 111.30, 110.77, 74.21, 52.37,
28.31.
3-(5-Bromo-2,3-dihydro-benzofuran-7-sulfonylamino)-thio-
phene-2-carboxylic Acid (4). The ester (3) (1 equiv, 15.6 g, 37.4
mmol) was stirred with lithium hydroxide monohydrate (5 equiv, 7.9
g, 187 mmol) in a tetrahydrofuran/methanol/water mixture (5:3:2; 40
mL) at 50 °C for 4 h. After this time, the organic solvents were
removed in vacuo, and the residue diluted with water (50 mL) and
then acidiﬁed to pH 1 with 6 M hydrochloric acid upon which
precipitation occurred. The precipitate was washed with water (3 × 50
mL), collected by ﬁltration, and dried in vacuo to give 4. Yield: 13 g,
32.2 mmol, 86%. Oﬀ-white solid. LC-MS: tR = 4.54 min. MS m/z 402/
404 [M − 1]−. HRMS: Calculated for C13H11BrNO5S2 403.9262,
Measured mass: 403.9246. 1H NMR (600 MHz, DMSO-d6) δ 10.11
(s, 1H), 7.79 (d, J = 5.5 Hz, 1H), 7.71−7.66 (m, 1H), 7.63−7.58 (m,
1H), 7.19 (d, J = 5.5 Hz, 1H), 4.67 (t, J = 8.8 Hz, 2H), 3.27−3.20 (m,
2H). 13C NMR (151 MHz, DMSO-d6) δ 164.75, 155.96, 141.69,
Figure 6. Blocking NRP1 is important for angiogenesis in a coculture assay. (A) Human dermal ﬁbroblasts were grown in a 24-well format to
conﬂuence. HUVECs were seeded, treated with medium supplemented with 0.1%DMSO as vehicle control (Veh), VEGF 25 ng/mL, 1 (30 μM), and
1 (30 μM) + VEGF 25 ng/mL and kept in culture for 4 days. Endothelial cells were then visualized by immunoﬂuorescence for Anti-von Willebrand.
(B) Quantitation of coculture assays in A. The bar graph shows the mean ± SEM network branch points, area, and length. Data corresponds to the
average of three independent experiments; *p < 0.05.
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benzofuran-5-sulfonyl-guanidino)-pentanoic Acid Methyl Ester (5).
The acid (4) (1 equiv, 13 g, 32.2 mmol) and bromo-tris-pyrrolidino-
phosphonium hexaﬂuorophosphate (PyBrOP; 1.1 equiv, 16.4 g, 35.4
mmol) were suspended in dichloromethane (100 mL) under nitrogen
(balloon) and stirred at 20 °C for 10 min. N,N-Diisopropylethylamine
(7 equiv, 39.2 mL, 225.4 mmol) was added to the mixture and stirred
for a further 15 min. The protected amino acid H-L-arginine(Pbf)-
OMe (hydrochloric acid salt; 1.1 equiv, 16.7 g, 35.4 mmol) was added
as a single portion, and the reaction was then stirred for 18 h at 20 °C.
After this time, the solvents were removed in vacuo and the resulting
residue dissolved in EtOAc (200 mL) washed with 1 M hydrochloric
acid (3 × 80 mL). The organic layer was washed with NaCl (aqueous
satd solution, 80 mL), dried (Mg2SO4), and concentrated in vacuo.
The residue was puriﬁed by ﬂash column chromatography (silica;
EtOAc in iso-hexane 50/50 to 0/100). The desired fractions were
collected and concentrated in vacuo to give 5. Yield: 21 g, 25.5 mmol,
79%. Oﬀ-white solid. LC-MS tR = 4.77 min. MS m/z −826/828 [M +
H]+. HRMS: Calculated for C33H41BrN5O9S3 826.1250. Measured
Mass: 826.1279. 1H NMR (600 MHz, DMSO-d6) δ 11.02 (s, 1H),
8.64 (d, J = 7.3 Hz, 1H), 7.73 (d, J = 5.3 Hz, 1H), 7.65 (s, 1H), 7.57
(s, 1H), 7.16 (d, J = 5.4 Hz, 1H), 4.67−4.54 (m, 2H), 4.41−4.30 (m,
1H), 3.65 (s, 3H), 3.19 (s, 2H), 3.10−3.02 (m, 2H), 2.93 (s, 2H), 2.47
(s, 3H), 2.42 (s, 3H), 1.97 (s, 3H), 1.84−1.66 (m, 2H), 1.50−1.43 (m,
1H), 1.40 (m, 6H). 13C NMR (151 MHz, DMSO-d6) δ 172.08,
163.43, 157.48, 156.11, 155.98, 141.05, 137.27, 133.99, 133.31, 131.47,
130.56, 128.27, 124.35, 121.26, 120.02, 116.29, 113.47, 110.67, 86.33,
73.99, 52.20, 52.04, 42.48, 40.10, 30.42, 29.02, 27.54, 22.12, 13.97.
(S)-2-{[3-(5-Bromo-2,3-dihydro-benzofuran-7-sulfonylamino)-thi-
ophene-2-carbonyl]-amino}-5-(2,2,4,6,7-pentamethyl-2,3-dihydro-
benzofuran-5-sulfonyl-guanidino)-pentanoic Acid (6). (S)-2-{[3-(5-
Bromo-2,3-dihydro-benzofuran-7-sulfonylamino)-thiophene-2-carbon-
yl]-amino}-5-(2,2,4,6,7-pentamethyl-2,3-dihydro-benzofuran-5-sulfon-
yl-guanidino)-pentanoic acid methyl ester (1 eq, 2.45 g, 2.96 mmol)
was stirred with 1 M lithium hydroxide (5 equiv, 14.82 mL mg, 14.82
mmol) in tetrahydrofuran (29 mL) at 20 °C for 3 h. After this time,
the organic solvents were removed in vacuo and the (aqueous) residue
Figure 7. Compound 1 in combination with VEGFA reduces
angiogenesis. (A) Representative pictures of mouse aortic rings
stained with isolectin B4 (red) and SMA (green). Rings were treated
with medium containing 0.1%DMSO as vehicle control (Veh), VEGF
25 ng/mL, 1 (30 μM), and 1 (30 μM) + VEGF 25 ng/mL. (B)
Sprouts outgrowth area was quantiﬁed using imageJ. Data represent
the average of three independent experiments ± SEM, ***P ≤ 0.001.
Figure 8. Compound 1 in combination with VEGFA reduces A375P
spheroid outgrowth. (A) A375P cells were resuspended and used to
generate spheroids as described in Materials and Methods. Then 24 h
after spheroid production, spheroids were imbedded in a collagen gel
and incubated in medium containing 0.1% DMSO as a vehicle control
(Veh), VEGF 25 ng/mL, 1 (30 μM), and 1 (30 μM) + VEGF 25 ng/
mL for 7 days. (B) Spheroid outgrowth area was measured by
quantifying the area corresponding to the invasion rim minus the area
of the core for at least four diﬀerent spheroids per condition. Data
from at least three independent experiments ± SEM are presented as
arbitrary units (a.u.) *p < 0.05.
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diluted with water (30 mL) and then acidiﬁed to pH 1 with 6 M
hydrochloric acid. Ethyl acetate (200 mL) was added to the resulting
suspension and, after thorough mixing, the organic layer separated.
The aqueous layer was further extracted with ethyl acetate (150 mL),
and the organic extracts were combined, washed with brine (saturated
aqueous solution; 3 × 75 mL), dried over magnesium sulfate, ﬁltered,
and the solvent removed in vacuo. The product (pale-yellow foam,
2.42 g, 100%) was used without further puriﬁcation. LC-MS: Rt 4.89
min. MS m/z −812/814 [M + H]+. HRMS: Calculated for
C32H39BrN5O9S3 812.1093. Measured mass: 812.1063.
1H NMR
(700 MHz, DMSO-d6, plus 20 μL of D2O, 353.2 K) δ 7.52 (dd, J = 2.2,
0.8 Hz, 1H), 7.38 (dt, J = 2.2, 1.2 Hz, 1H), 7.29 (d, J = 5.4 Hz, 1H),
7.14 (d, J = 5.4 Hz, 1H), 4.54−4.45 (m, 2H), 4.26 (dd, J = 8.6, 4.8 Hz,
1H), 3.19−3.06 (m, 4H), 2.95 (s, 2H), 2.57 (s, 1H), 2.46−2.43 (m,
3H), 2.01 (s, 3H), 1.83−1.74 (m, 1H), 1.74−1.65 (m, 1H), 1.64−1.54
(m, 2H), 1.42 (s, 7H). 13C NMR (151 MHz, DMSO-d6, plus 20 μL
D2O) δ 173.65, 163.18, 158.46, 158.25, 157.51, 156.18, 156.13, 155.49,
137.32, 131.53, 128.35, 124.42, 118.17, 116.36, 116.19, 114.22, 109.91,
86.38, 51.74, 42.44, 34.16, 28.38, 28.31, 28.18, 18.95, 17.62, 12.25.
General Procedure for Suzuki−Miyaura Couplings. (S)-2-{[3-(5-
Bromo-2,3-dihydro-benzofuran-7-sulfonylamino)-thiophene-2-carbon-
yl]-amino}-5-(2,2,4,6,7-pentamethyl-2,3-dihydro-benzofuran-5-sulfon-
yl-guanidino)-pentanoic acid (approx 1 g, 1.23 mmol, 1.0 equiv),
boronic ac id (1 .85 mmol , 1 .5 equiv) , and tet rak i s -
(triphenylphosphine)palladium(0) (71 mg, 0.06 mmol, 0.05 equiv)
were suspended in degassed 1,2-dimethoxyethane (3 mL). Potassium
phosphate (4.92 mmol, tribasic, 2 M aqueous solution 2.46 mL, 4
equiv), also degassed, was further added and the reaction mixture
heated using microwave conditions (100 W, 90 °C, ramp time = 10
min). After this time, the solvent was removed in vacuo and the
resulting residue was partitioned between ethyl acetate (200 mL) and
hydrochloric acid (1 M aqueous solution; 150 mL). The phases were
separated and the aqueous phase further extracted with ethyl acetate
Figure 9. Compound 1 blocks the production of TGFβ by Nrp1+
Tregs in the presence of tumor cell-derived factors. (A) Primary T
cells were isolated from the spleens of mice and puriﬁed for CD4 and
CD304 (Nrp1) expression. The expression of these cell surface
receptors as well as FOXP3 expression were veriﬁed by ﬂow
cytometry. (B) Nrp1+ Tregs were either exposed or not to 500 nM
1 for 2 h prior to incubation with glioma conditioned media (GCM).
Production of TGFβ by the cells was assessed via ELISA after 12 h.
The lanes correspond to media alone (Ctr), media with GCM (GCM
alone), media with 1377 (1377), and then Nrp1+ Treg cells exposed to
GCM (+GCM), or GCM + 1377 (1377 + GCM).
Table 5. IV PK Data for Selected Compounds
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(200 mL). The organic extracts were combined, washed with brine
(saturated, aqueous solution; 2 × 100 mL), dried over magnesium
sulfate, ﬁltered, and the solvent removed in vacuo. The crude product
(typically a yellow solid; approx 1.5 g) was puriﬁed by ﬂash column
chromatography on silica gel (eluent: dichloromethane increasing to
dichloromethane/methanol; 75:25) to aﬀord the desired product.
N2-(3-((5-(2-Formylphenyl)-2,3-dihydrobenzofuran)-7-
sulfonamido)thiophene-2-carbonyl)-Nω-((2,2,4,6,7-pentamethyl-
2,3-dihydrobenzofuran-5-yl)sulfonyl)-L-arginine (7a). The general
Suzuki method was used but with 2-formylphenylboronic acid (1.5
equiv). The product was isolated as a pale-yellow solid, 810 mg, 77%
(LC-MS Rt 4.81 min. MS m/z −838 [M + H]+). HRMS: Calculated
for C39H44BrN5O10S3 838.2247. Measured mass: 838.2250.
1H NMR
(700 MHz, DMSO-d6, plus 80 μL D2O) δ 9.72 (s, 1H), 7.87 (d, J = 7.7
Hz, 1H), 7.73−7.68 (m, 1H), 7.65−7.61 (m, 1H), 7.63−7.49 (m, 3H),
7.43−7.34 (m, 2H), 7.15 (d, J = 5.4 Hz, 1H), 4.64 (t, J = 8.7 Hz, 2H),
4.28−4.22 (m, 1H), 3.20 (t, J = 8.9 Hz, 2H), 3.07−3.00 (m, 2H), 2.89
(s, 2H), 2.41 (s, 3H), 2.37 (s, 3H), 2.02 (s, 2H), 1.89 (s, 2H), 1.80−
1.73 (m, 1H), 1.68 (m, 1H), 1.34 (s, 6H). 13C NMR (176 MHz,
DMSO-d6) δ 191.41, 173.07, 163.36, 157.39, 156.53, 143.13, 141.22,
137.20, 133.95, 133.25, 131.86, 131.47, 131.39, 130.89, 130.08, 129.45,
128.75, 128.68, 128.12, 127.99, 127.88, 124.29, 120.00, 119.48, 116.22,
113.41, 86.26, 73.82, 52.09, 42.40, 28.25, 27.54, 18.90, 17.54, 12.16.
N2-(3-((5-(3-Formylphenyl)-2,3-dihydrobenzofuran)-7-
sulfonamido)thiophene-2-carbonyl)-Nω-((2,2,4,6,7-pentamethyl-
2,3-dihydrobenzofuran-5-yl)sulfonyl)-L-arginine (7b). The general
Suzuki method was used but with 3-formylphenylboronic acid (1.5
equiv). HRMS: Calculated for C39H44N5O10S3 838.2250. Measured
mass: 838.225.5. 1H NMR (700 MHz, DMSO-d6) δ 11.06 (s, 1H),
10.08 (s, 1H), 8.48 (d, J = 7.6 Hz, 1H), 8.12 (t, J = 1.7 Hz, 1H), 7.94
(dt, J = 7.8, 1.3 Hz, 1H), 7.86 (dt, J = 3.9, 2.3 Hz, 2H), 7.77 (d, J = 1.9
Hz, 1H), 7.69−7.64 (m, 2H), 7.22 (d, J = 5.5 Hz, 1H), 4.67 (td, J =
8.8, 2.5 Hz, 2H), 4.32−4.26 (m, 1H), 3.24 (t, J = 8.8 Hz, 2H), 3.05
(hept, J = 6.7 Hz, 2H), 2.91 (s, 2H), 2.45 (s, 3H), 2.40 (s, 3H), 2.06
(s, 3H), 1.94 (s, 3H), 1.84−1.76 (m, 1H), 1.75−1.66 (m, 1H), 1.38 (s,
3H), 1.37 (s, 3H). 13C NMR (176 MHz, DMSO-d6) δ 193.18, 173.07,
163.39, 157.44, 156.51, 156.01, 141.26, 139.42, 137.25, 136.87, 134.00,
132.29, 132.07, 131.45, 131.34, 130.16, 129.92, 129.05, 128.70, 127.84,
127.76, 124.79, 124.32, 120.27, 119.99, 118.04, 86.28, 73.81, 52.10,
42.39, 28.28, 28.24, 20.73, 18.90, 17.54, 14.06, 12.17.
General Procedure for Reductive Amination. A solution of the
aldehyde (1 equiv) in tetrahydrofuran/methanol (1:1, 1.5 mL) was
added to the amine (commercially available; 1.1 equiv) followed by
acetic acid (1−2 drops ∼ pH 6). The reaction was stirred at 20 °C for
2 h before sodium cyanoborohydride (2 equiv) in methanol (0.1 mL)
was added in one portion. The reaction was stirred for a further 16 h at
20 °C. The reaction was ﬁltered through a preconditioned SCX-2 (1
g) cartridge and the product eluted with 2 M ammonia in methanol.
Solvent evaporation gave the product as a yellow oil, which was
dissolved in dichloromethane/triﬂuoroacetic acid (1:1, 8 mL) and
stirred at 20 °C for 1 h. The solvent was removed in vacuo and the
crude residue dissolved in dimethyl sulfoxide and puriﬁed by (mass-
directed) preparative LC-MS using a preparative C-18 column
(Phenomenex Luna C18 (2), 100 mm × 21.2 mm, 5 μM) and a
linear AB gradient of 5−95% for B over 12 min at a ﬂow rate of 20
mL/min, where, (i) eluent A was 0.1% formic acid/water and eluent B
was 0.1% formic acid/methanol or, (ii) eluent A was 10 mM
ammonium bicarbonate (pH 9) and eluent B was 100% methanol. The
puriﬁed compounds were isolated via solvent evaporation and carried
through to Pbf removal.
General Procedure for Pbf Removal. The residue was dissolved in
dichloromethane/triﬂuoroacetic acid (1:1, 5 mL) and stirred at room
temperature for 1 h. The solvent was removed in vacuo and the crude
residue dissolved in dimethyl sulfoxide and puriﬁed by (mass-directed)
preparative LC-MS using a preparative C-18 column (Phenomenex
Luna C18 (2), 100 mm × 21.2 mm, 5 μM) and a linear AB gradient of
5−95% for B over 12 min at a ﬂow rate of 20 mL/min, where eluent A
was 0.1% formic acid/water and eluent B was 0.1% formic acid/




(9a). The general Suzuki method was used but with phenylboronic
acid 2.4 mmol scale reaction. Intermediate unsubstituted product 8,
pale-yellow solid, 1.89 g, 2.3 mmol, 97%, Rt 3.31 min. MS m/z −812/
814 [M + H]+. Standard Pbf removal 1 × 0.062 mmol scale reaction
gave a white solid, 48 mg, 0.059 mmol, 96%. Rt 3.41 min. MS m/z
−810 [M + H]+. HRMS (ES −ve): Calculated for C25H26N5O6S2
556.1324. Measured mass: 556.1315. 1H NMR (600 MHz, DMSO-d6)
δ 10.06 (s, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.55 (d, J = 1.9 Hz, 1H),
7.53−7.49 (m, 2H), 7.42 (t, J = 7.7 Hz, 2H), 7.34−7.29 (m, 1H), 7.23
(d, J = 5.4 Hz, 1H), 7.17 (d, J = 5.4 Hz, 1H), 6.88 (bs, 2H), 4.73−4.44
(m, 2H), 4.22 (m, J = 6.8 Hz, 1H), 3.25−3.15 (m, 5H), 1.84 (m, 1H),
1.77−1.67 (m, 4H). 13C NMR (151 MHz, DMSO) δ 163.60, 157.38,
156.16, 150.47, 140.24, 135.19, 130.85, 129.44, 128.44, 127.29, 127.24,





ginine (9b). The standard reductive amination procedure was carried
out with 7a and (1H-imidazol-4-yl)methanamine and then Pbf
removal to give 9b as a white solid, 8.9 mg, 30%. Rt 4.48 min. MS
m/z −667 [M + H]+. HRMS (ES +ve): Calculated for C30H34N8O6S2
666.2121. Measured mass: 667.2092. 1H NMR (600 MHz, DMSO-d6)
δ 11.10 (s, 1H), 8.57 (d, J = 7.5 Hz, 1H), 7.82−7.77 (m, 1H), 7.70 (d,
J = 5.5 Hz, 2H), 7.66−7.61 (m, 2H), 7.52−7.45 (m, 3H), 7.41 (d, J =
1.7 Hz, 1H), 7.23 (dd, J = 7.4, 1.7 Hz, 1H), 7.20 (d, J = 5.4 Hz, 1H),
4.70 (t, J = 8.8 Hz, 2H), 4.46−4.41 (m, 2H), 4.39−4.31 (m, 1H), 4.19
(s, 2H), 3.29−3.18 (m, 2H), 3.17−3.07 (m, 2H), 1.93−1.83 (m, 1H),
1.82−1.71 (m, 1H), 1.61−1.46 (m, 1H). 13C NMR (151 MHz,
DMSO-d6) δ 173.15, 158.76, 158.73, 156.85, 156.11, 141.45, 140.49,
131.48, 131.42, 131.19, 130.55, 130.32, 129.74, 129.42, 129.02, 128.16,
127.40, 119.85, 119.71, 116.92, 114.98, 112.97, 73.70, 52.10, 47.71,




ginine (9c). The standard reductive amination procedure was carried
out with 7a and (1H-pyrazol-3-yl)methanamine) and then Pbf
removal to give a white solid, 12.5 mg, 44%. Rt 4.44 min. MS m/z
−667 [M + H]+. HRMS (ES +ve): Calculated for C30H35N8O6S2
667.2121. Measured mass: 667.2061. 1H NMR (600 MHz, DMSO-d6
plus 20 μL of D2O) δ 7.54 (d, J = 7.5 Hz, 1H), 7.48 (d, J = 2.0 Hz,
1H), 7.47 (d, J = 1.8 Hz, 1H), 7.35−7.31 (m, 2H), 7.31−7.27 (m,
1H), 7.23 (d, J = 5.4 Hz, 1H), 7.20 (s, 1H), 7.18 (d, J = 5.4 Hz, 1H),
7.11 (dd, J = 7.4, 1.5 Hz, 1H), 6.15 (d, J = 2.0 Hz, 1H), 4.64−4.53 (m,
3H), 4.21−4.15 (m, 1H), 3.20−3.12 (m, 5H), 1.83−1.74 (m, 1H),
1.72−1.58 (m, 4H). 13C NMR (151 MHz, DMSO-d6) δ 174.42,
163.18, 156.91, 155.28, 150.03, 140.91, 136.32, 131.57, 129.76, 129.39,
129.21, 127.58, 127.38, 127.34, 127.15, 127.06, 126.71, 122.86, 113.99,




ginine (9d). The standard reductive amination procedure was carried
out with 7a and (1H-pyrazol-4-yl)methanamine) and then Pbf
removal to give intermediate product 8, as a white solid, 8.6 mg,
30%. Rt 4.40 min. MS m/z −667 [M+ 1]+. HRMS (ES +ve):
Calculated for C30H35N8O6S2 667.2121. Measured mass: 667.2081.
1H
NMR (600 MHz, DMSO-d6) δ 10.01 (s, 1H), 7.58−7.48 (m, 5H),
7.35−7.27 (m, 2H), 7.24−7.18 (m, 3H), 7.13 (dd, J = 7.4, 1.5 Hz,
1H), 4.65−4.54 (m, 2H), 4.16 (d, J = 6.0 Hz, 1H), 3.71−3.60 (m,
4H), 3.20−3.11 (m, 4H), 1.81−1.74 (m, 1H), 1.70−1.54 (m, 3H). 13C
NMR (151 MHz, DMSO-d6) δ 174.68, 163.09, 156.88, 155.31, 150.01,
141.11, 131.37, 129.84, 129.39, 129.30, 127.67, 127.52, 127.45, 127.30,
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arginine (9e). The standard reductive amination procedure was
carried out with 7a and pyridin-2-ylmethanamine and then Pbf
removal to give a white solid, 6.3 mg, 21%. Rt 4.62 min. MS m/z −678
[M + H]+. HRMS (ES +ve): Calculated for C32H36N7O6S2 678.2169.
Measured mass: 678.2175. 1H NMR (600 MHz, DMSO-d6) δ 11.11
(s, 1H), 9.39 (s, 1H), 8.59−8.53 (m, 1H), 8.42 (dt, J = 4.9, 1.4 Hz,
1H), 7.79 (td, J = 7.7, 1.8 Hz, 1H), 7.73 (dd, J = 7.7, 1.4 Hz, 1H), 7.68
(d, J = 5.5 Hz, 1H), 7.60−7.50 (m, 2H), 7.48 (td, J = 7.5, 1.4 Hz, 1H),
7.42−7.33 (m, 3H), 7.32 (d, J = 7.9 Hz, 1H), 7.26−7.16 (m, 2H),
4.74−4.63 (m, 2H), 4.39−4.32 (m, 1H), 4.18 (s, 2H), 4.16 (d, J = 4.2
Hz, 2H), 3.23−3.08 (m, 3H), 1.92−1.83 (m, 1H), 1.81−1.70 (m, 1H),
1.57−1.49 (m, 2H).
(3-((5-(3-(Morpholinomethyl)phenyl)-2,3-dihydrobenzofuran)-7-
sulfonamido)thiophene-2-carbonyl)-L-arginine (10a). The standard
reductive amination procedure was carried out with 7b on a 0.1 mmol
scale with morpholine (22 mg, 0.25 mmol) and then Pbf removal to
give 10a as an oﬀ-white solid, 38 mg, 0.058 mmol, 58%. LC-MS(b) Rt
2.68 min. MS m/z −657 [M + H]+. HRMS: ES (−) Calculated for
C30H35N6O7S2 655.2009. Measured mass: 655.2022.
1H NMR (700
MHz, DMSO-d6, plus 50 μL D2O) δ 7.82−7.78 (m, 1H), 7.77−7.74
(m, 1H), 7.74−7.72 (m, 1H), 7.70−7.66 (m, 1H), 7.64 (d, J = 5.5 Hz,
1H), 7.53 (td, J = 7.7, 3.5 Hz, 1H), 7.45 (dd, J = 15.8, 7.6 Hz, 1H),
7.17 (d, J = 5.4 Hz, 1H), 4.66 (t, J = 8.8 Hz, 2H), 4.39 (s, 1H), 4.36−
4.29 (m, 2H), 3.98−3.94 (m, 1H), 3.63 (t, J = 12.7 Hz, 1H), 3.31−
3.19 (m, 3H), 3.18−3.13 (m, 1H), 3.10 (t, J = 7.2 Hz, 2H), 2.75 (s,
2H), 1.86 (ddt, J = 13.7, 10.7, 5.5 Hz, 1H), 1.79−1.70 (m, 1H), 1.60−
1.46 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 173.14, 159.12,
158.89, 158.66, 141.32, 139.14, 131.98, 131.95, 131.31, 130.30, 130.11,
129.88, 129.64, 129.62, 119.88, 119.07, 117.12, 115.18, 113.24, 73.82,




ginine (10b). The standard reductive amination procedure was carried
out with 7b and (1H-imidazol-4-yl)methanamine and then Pbf
removal to give a white solid, 9.6 mg, 32%. Rt 4.30 min. MS m/z
667 [M + H]+. HRMS (ES +ve): Calculated for C30H35N8O6S2
667.2121. Measured mass: 667.2071. 1H NMR (600 MHz, DMSO-
d6) δ 11.10 (s, 1H), 8.56 (d, J = 7.6 Hz, 1H), 7.82 (q, J = 1.4 Hz, 1H),
7.81−7.75 (m, 2H), 7.71 (t, J = 5.7 Hz, 1H), 7.69−7.65 (m, 2H), 7.62
(s, 2H), 7.52 (t, J = 7.7 Hz, 1H), 7.50−7.44 (m, 1H), 7.18 (d, J = 5.5
Hz, 1H), 4.69 (t, J = 8.8 Hz, 2H), 4.37−4.32 (m, 3H), 3.33−3.20 (m,
2H), 3.17−3.07 (m, 2H), 1.93−1.83 (m, 1H), 1.81−1.70 (m, 1H),
1.62−1.46 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 173.15,
163.49, 159.06, 158.84, 158.61, 141.34, 138.96, 132.09, 131.97, 130.33,
129.53, 129.07, 128.94, 128.18, 127.08, 124.62, 120.30, 119.75, 119.14,





ginine (10c). The standard reductive amination procedure was carried
out with 7b and (1H-pyrazol-3-yl)methanamine) and then Pbf
removal to give a white solid, 13.1 mg, 48%. Rt 4.46 min. MS m/z
−667 [M+ 1]+. HRMS (ES +ve): Calculated for C30H35N8O6S2
667.2121. Measured mass: 667.2056. 1H NMR (400 MHz, DMSO-
d6) δ 11.08 (s, 1H), 9.45−9.39 (m, 2H), 8.53 (d, J = 7.6 Hz, 1H),
7.84−7.82 (m, 1H), 7.81 (d, J = 2.2 Hz, 1H), 7.80−7.77 (m, 2H),
7.68−7.62 (m, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.46 (dt, J = 7.6, 1.5 Hz,
1H), 7.18 (d, J = 5.4 Hz, 1H), 6.43 (d, J = 2.3 Hz, 1H), 4.68 (t, J = 8.8
Hz, 2H), 4.41−4.31 (m, 1H), 4.26 (t, J = 5.6 Hz, 2H), 4.20 (t, J = 5.5
Hz, 2H), 3.35−3.20 (m, 2H), 3.12 (q, J = 6.8 Hz, 2H), 1.94−1.80 (m,
1H), 1.83−1.68 (m, 1H), 1.63−1.43 (m, 2H). 13C NMR (151 MHz,
DMSO-d6) δ 173.14, 163.49, 156.76, 156.29, 142.42, 141.34, 138.86,
132.61, 132.13, 131.98, 130.34, 129.45, 129.20, 128.97, 128.30, 126.94,





ginine (10d). The standard reductive amination procedure was carried
out with 7b and (1H-pyrazol-4-yl)methanamine) and then Pbf
removal to give an oﬀ-white solid, 11.2 mg, 40%. Rt 4.38 min. MS
m/z −667 [M + H]+. HRMS (ES +ve): Calculated for C30H35N8O6S2
667.2121. Measured mass: 667.2069. 1H NMR (600 MHz, DMSO-d6)
δ 12.44 (bs, 1H), 9.98 (d, J = 8.4 Hz, 1H), 7.82−7.77 (m, 2H), 7.76−
7.70 (m, 1H), 7.67 (s, 2H), 7.50 (dd, J = 10.0, 1.8 Hz, 2H), 7.36 (t, J =
7.7 Hz, 1H), 7.28 (d, J = 5.4 Hz, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.18
(d, J = 5.4 Hz, 1H), 6.94 (s, 2H), 4.64−4.50 (m, 2H), 4.31−4.23 (m,
1H), 4.03−3.94 (m, 2H), 3.97−3.89 (m, 2H), 3.22−3.13 (m, 2H),
1.84−1.76 (m, 1H), 1.73−1.51 (m, 3H). 13C NMR (151 MHz,
DMSO) δ 176.18, 162.97, 156.85, 155.96, 150.07, 139.89, 135.60,
131.38, 130.33, 128.89, 128.76, 128.22, 127.67, 127.40, 126.80, 126.28,
125.61, 125.56, 124.71, 123.23, 114.61, 113.21, 71.73, 53.10, 49.66,




arginine (10e). The standard reductive amination procedure was
carried out with 7b and pyridin-2-ylmethanamine and then Pbf
removal to give a white solid, 8.8 mg, 31%. Rt 4.72 min. MS m/z −678
[M + H]+. HRMS (ES +ve): Calculated for C32H36N7O6S2 678.2169.
Measured mass: 678.2166. 1H NMR (600 MHz, DMSO-d6, plus 20 μL
of D2O) δ 8.65 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.88 (td, J = 7.7, 1.8 Hz,
1H), 7.81 (dt, J = 11.6, 1.6 Hz, 2H), 7.79−7.75 (m, 1H), 7.70−7.63
(m, 2H), 7.55−7.45 (m, 3H), 7.49−7.41 (m, 1H), 7.18 (d, J = 5.5 Hz,
1H), 4.67 (t, J = 9.0 Hz, 2H), 4.39−4.27 (m, 5H), 3.32−3.22 (m, 2H),
3.11 (t, J = 7.1 Hz, 2H), 1.92−1.82 (m, 1H), 1.80−1.69 (m, 1H),
1.60−1.46 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 173.14,
163.48, 158.59, 158.37, 158.15, 151.94, 149.09, 141.33, 138.85, 137.47,
132.56, 132.14, 131.98, 130.35, 129.46, 129.25, 128.97, 128.36, 126.97,
124.61, 123.76, 123.39, 120.28, 119.76, 73.82, 52.07, 50.11, 49.88,
40.32, 28.34, 27.34, 25.57.
(S)-5-Guanidino(Pbf)-2-({3-[5-(2-piperidin-1-ylmethyl-phenyl)-
2,3-dihydro-benzofuran-7-sulfonylamino]-thiophene-2-carbonyl}-
amino)-pentanoic Acid (11a). The standard reductive amination
procedure was carried out with 7a and piperidine and then Pbf
removal to give a white solid, 3 mg, 23%. Rt 4.61 min. MS m/z −655
[M + H]+. HRMS (ES +ve): Calculated for C31H39N6O6S2 655.2372.
Measured mass: 655.2372. 1H NMR (600 MHz, DMSO-d6) δ 11.11
(s, 1H), 9.23 (s, 1H), 8.56 (d, J = 7.6 Hz, 1H), 7.76−7.68 (m, 2H),
7.68−7.62 (m, 1H), 7.57−7.50 (m, 2H), 7.48 (d, J = 1.7 Hz, 1H), 7.43
(d, J = 1.8 Hz, 1H), 7.27 (dd, J = 6.9, 2.0 Hz, 1H), 7.20 (d, J = 5.4 Hz,
1H), 4.76−4.66 (m, 2H), 4.38−4.31 (m, 1H), 4.27−4.17 (m, 2H),
3.36−3.21 (m, 2H), 3.17−3.06 (m, 4H), 1.92−1.83 (m, 1H), 1.81−
1.70 (m, 1H), 1.67−1.47 (m, 7H), 1.27−1.19 (m, 1H). 13C NMR
(151 MHz, DMSO-d6) δ 173.15, 163.54, 158.33, 158.11, 156.72,
156.17, 141.83, 131.68, 131.55, 131.19, 130.90, 130.35, 129.59, 127.64,




amino]-5-guanidino-pentanoic Acid (11b). The standard reductive
amination procedure was carried out with 7a and piperidine-4-
carboxamide and then Pbf removal to give a white solid, 4 mg, 32%. Rt
4.43 min. MS m/z −698 [M + H]+. HRMS (ES +ve): Calculated for
C32H40N7O7S2 698.2430. Measured mass: 698.2401.
1H NMR (600
MHz, DMSO-d6, plus 50 μL of D2O) δ 7.72−7.65 (m, 2H), 7.55−7.48
(m, 2H), 7.44 (s, 1H), 7.38 (d, J = 1.7 Hz, 1H), 7.26−7.21 (m, 1H),
7.17 (d, J = 5.4 Hz, 1H), 4.73−4.62 (m, 2H), 4.32 (dd, J = 10.0, 5.0
Hz, 1H), 4.25−4.15 (m, 2H), 3.32−3.16 (m, 4H), 3.10 (t, J = 7.1 Hz,
2H), 2.65−2.56 (m, 2H), 2.23 (tt, J = 11.5, 3.8 Hz, 1H), 1.91−1.82
(m, 1H), 1.85−1.63 (m, 5H), 1.60−1.45 (m, 2H). 13C NMR (151
MHz, DMSO-d6, plus 50 μL of D2O) δ 174.94, 173.00, 163.39, 158.74,
158.53, 158.31, 141.74, 141.10, 131.70, 131.61, 131.22, 130.92, 130.23,
129.80, 128.45, 127.25, 127.17, 120.02, 119.62, 117.85, 73.77, 56.51,
51.96, 51.18, 40.19, 28.33, 27.19, 25.42.
(S)-5-Guanidino-2-[(3-{5-[2-(4-methylcarbamoyl-piperidin-1-yl-
methyl)-phenyl]-2,3-dihydro-benzofuran-7-sulfonylamino}-
thiophene-2-carbonyl)-amino]-pentanoic Acid (11c). The standard
reductive amination procedure was carried out with 7a and N-
methylpiperidine-4-carboxamide and then Pbf removal to give a white
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solid, 9.8 mg, 29%. Rt 4.51 min. MS m/z −712 [M + H]+. HRMS (ES
+ve): Calculated for C33H42N7O7S2 712.2587. Measured mass:
712.2426. 1H NMR (600 MHz, DMSO-d6, plus 50 μL of D2O) δ
7.74−7.67 (m, 2H), 7.56−7.48 (m, 2H), 7.45 (s, 1H), 7.40 (d, J = 1.7
Hz, 1H), 7.27−7.22 (m, 1H), 7.18 (d, J = 5.4 Hz, 1H), 4.69 (td, J =
8.7, 2.3 Hz, 2H), 4.34 (dd, J = 9.9, 5.0 Hz, 1H), 4.27−4.18 (m, 2H),
3.30−3.17 (m, 4H), 3.11 (t, J = 7.1 Hz, 2H), 2.69−2.61 (m, 1H), 2.54
(s, 3H), 2.22 (td, J = 11.2, 5.7 Hz, 1H), 1.92−1.82 (m, 1H), 1.81−1.67
(m, 6H), 1.61−1.46 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ
172.98, 158.50, 158.29, 156.45, 156.18, 141.78, 131.73, 131.64, 131.57,
131.15, 130.91, 130.26, 129.66, 128.38, 127.31, 119.95, 119.75, 118.03,




thiophene-2-carbonyl)-amino]-pentanoic Acid (11d). The standard
reductive amination procedure was carried out with 7a and 4-
(piperidin-4-yl)morpholine and then then Pbf removal to give a white
solid, 5.8 mg, 18%. Rt 3.84 min. MS m/z −640 [M + H]+). HRMS (ES
−ve): Calculated for C35H46N7O7S2 738.2749. Measured mass:
738.2744. 1H NMR (700 MHz, DMSO-d6, plus 25 μL of D2O at 80
°C) δ 7.71−7.65 (m, 2H), 7.53−7.49 (m, 2H), 7.48−7.43 (m, 2H),
7.28−7.23 (m, 1H), 7.18 (d, J = 5.4 Hz, 1H), 4.70 (td, J = 8.6, 1.5 Hz,
2H), 4.38 (dd, J = 9.4, 5.2 Hz, 1H), 4.10−4.06 (m, 2H), 3.84 (s, 4H),
3.31−3.24 (m, 2H), 3.15 (t, J = 7.2 Hz, 6H), 2.16−2.10 (m, 2H),
1.95−1.87 (m, 1H), 1.85−1.76 (m, 2H), 1.64−1.52 (m, 2H), 1.32−
1.26 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 173.14, 163.55,
158.71, 158.49, 158.26, 156.15, 141.45, 131.78, 131.42, 130.94, 130.40,
127.45, 119.82, 119.24, 118.16, 117.28, 115.33, 113.38, 112.94, 73.71,
63.48, 63.33, 53.56, 52.08, 48.52, 42.85, 41.83, 28.41, 27.33, 25.58.
Cyanomethyl-piperidin-1-ylmethyl)-phenyl]-2,3-dihydro-benzo-
furan-7-sulfonylamino}-thiophene-2-carbonyl)-amino]-5-guanidi-
no-pentanoic Acid (11e). The standard reductive amination
procedure was carried out with 7a and 2-(piperidin-4-yl)acetonitrile
and then then Pbf removal to give a white solid, 7.3 mg, 23%. Rt 4.52
min. MS m/z −694.5 [M + H]+. HRMS (ES +ve): Calculated for
C33H40N7O6S2 694.2482. Measured mass: 694.2451.
1H NMR (600
MHz, DMSO-d6, plus 20 μL of D2O) δ 7.74−7.67 (m, 3H), 7.56−7.49
(m, 3H), 7.48−7.44 (m, 1H), 7.45−7.40 (m, 1H), 7.26 (dd, J = 6.6,
2.3 Hz, 1H), 7.19 (d, J = 5.5 Hz, 1H), 4.75−4.64 (m, 3H), 4.33 (dd, J
= 10.0, 5.0 Hz, 1H), 4.21 (s, 2H), 3.26 (q, J = 7.9 Hz, 2H), 3.24−3.18
(m, 3H), 3.11 (t, J = 7.1 Hz, 3H), 2.69−2.57 (m, 2H), 2.54 (d, J = 5.3




amino)-pentanoic Acid (12a). The standard reductive amination
procedure was carried out with 7b and piperidine and then Pbf
removal to give a white solid, 8.6 mg, 55%. Rt 4.59 min. MS m/z −655
[M + H]+. HRMS (ES +ve): Calculated for C35H46N7O7S2 698.2430.
Measured mass: 698.2407. 1H NMR (600 MHz, DMSO-d6) δ 11.10
(s, 1H), 9.48 (s, 1H), 8.56 (d, J = 7.5 Hz, 1H), 7.84 (d, J = 1.8 Hz,
1H), 7.78 (q, J = 1.8 Hz, 2H), 7.72 (dt, J = 8.1, 1.2 Hz, 1H), 7.67 (d, J
= 5.5 Hz, 1H), 7.61 (t, J = 5.7 Hz, 1H), 7.55 (t, J = 7.7 Hz, 1H), 7.47
(dt, J = 7.6, 1.3 Hz, 1H), 7.18 (d, J = 5.5 Hz, 1H), 4.69 (td, J = 8.6, 1.7
Hz, 2H), 4.39−4.31 (m, 3H), 3.35 (d, J = 11.7 Hz, 2H), 3.31−3.22
(m, 2H), 3.15−3.08 (m, 2H), 2.96−2.86 (m, 2H), 1.92−1.80 (m, 3H),
1.79−1.73 (m, 1H), 1.73−1.67 (m, 1H), 1.66−1.58 (m, 2H), 1.57−
1.49 (m, 1H), 1.42−1.32 (m, 1H). 13C NMR (151 MHz, DMSO-d6) δ
173.15, 163.48, 158.06, 157.85, 156.70, 156.35, 139.09, 132.00, 131.95,
130.62, 130.30, 129.62, 129.35, 127.51, 124.62, 119.82, 113.14, 73.84,
58.99, 52.04, 51.92, 36.53, 28.33, 27.35, 25.56, 22.56, 21.35.
(S)-2-[(3-{5-[3-(4-Carbamoyl-piperidin-1-ylmethyl)-phenyl]-2,3-
dihydro-benzofuran-7-sulfonylamino}-thiophene-2-carbonyl)-
amino]-5-guanidino-pentanoic Acid (12b). The standard reductive
amination procedure was carried out with 7b and piperidine-4-
carboxamide and then Pbf removal to give a white solid, 8 mg, 57%. Rt
4.37 min. MS m/z −698 [M + H]+. HRMS (ES +ve): Calculated for
C32H40N7O7S2 698.2430. Measured mass: 698.2437.
1H NMR (600
MHz, DMSO-d6 plus 50 μL of D2O) δ 7.81 (d, J = 1.8 Hz, 1H), 7.74
(d, J = 2.1 Hz, 2H), 7.70−7.67 (m, 1H), 7.64 (d, J = 5.4 Hz, 1H),
7.56−7.51 (m, 1H), 7.45 (d, J = 7.7 Hz, 1H), 7.18 (d, J = 5.5 Hz, 1H),
4.69−4.64 (m, 2H), 4.34−4.29 (m, 3H), 3.40 (d, J = 11.8 Hz, 2H),
3.34−3.19 (m, 4H), 3.10 (t, J = 7.1 Hz, 2H), 3.00−2.91 (m, 2H),
2.42−2.33 (m, 1H), 1.92 (d, J = 12.5 Hz, 2H), 1.89−1.81 (m, 1H),
1.78−1.69 (m, 4H), 1.58−1.47 (m, 1H). 13C NMR (151 MHz,
DMSO-d6) δ 174.89, 174.76, 173.14, 163.49, 158.71, 158.49, 141.33,
139.07, 132.00, 131.95, 130.58, 130.35, 130.29, 129.62, 129.34, 129.03,
127.52, 124.60, 120.33, 119.84, 73.84, 59.12, 52.07, 51.03, 48.80,
40.32, 27.34, 25.73, 25.57, 23.57.
(S)-5-Guanidino-2-[(3-{5-[3-(4-methylcarbamoyl-piperidin-1-yl-
methyl)-phenyl]-2,3-dihydro-benzofuran-7-sulfonylamino}-
thiophene-2-carbonyl)-amino]-pentanoic Acid (12c). The standard
reductive amination procedure was carried out with 7a and N-
methylpiperidine-4-carboxamide and then Pbf removal to give a white
solid, 9.0 mg, 27%. Rt 4.50 min. MS m/z −712 [M + 1]+. HRMS (ES
+ve): Calculated for C33H43N7O7S2 712.2587. Measured mass:
712.2591. 1H NMR (600 MHz, DMSO-d6, plus 50 μL of D2O) δ
7.68 (d, J = 1.9 Hz, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.49−7.45 (m, 1H),
7.43−7.40 (m, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 5.4 Hz, 1H),
7.22 (dt, J = 7.6, 1.4 Hz, 1H), 7.18 (d, J = 5.4 Hz, 1H), 4.65−4.54 (m,
2H), 4.26−4.20 (m, 1H), 3.55 (s, 2H), 3.25−3.18 (m, 4H), 2.90−2.83
(m, 2H), 2.54 (d, J = 4.6 Hz, 3H), 2.07 (dt, J = 15.8, 5.5 Hz, 1H),
2.03−1.96 (m, 2H), 1.87−1.78 (m, 1H), 1.71 (qt, J = 10.1, 4.8 Hz,
3H), 1.65−1.54 (m, 4H).
(S)-5-Guanidino-2-[(3-{5-[3-(4-morpholin-4-yl-piperidin-1-yl-
methyl)-phenyl]-2,3-dihydro-benzofuran-7-sulfonylamino-thio-
phene-2-carbonyl)-amino]-pentanoic Acid (12d). The standard
reductive amination procedure was carried out with 7b and 4-
(piperidin-4-yl)morpholine and then then Pbf removal to give a white
solid, 9.5 mg, 29%. Rt 3.72 min. MS m/z −740 [M + H]+. HRMS (ES
+ve): Calculated for C35H46N7O7S2 740.2900. Measured mass:
740.2964. 1H NMR (600 MHz, DMSO-d6, plus 50 μL of D2O) δ
7.81 (s, 1H), 7.75 (d, J = 2.0 Hz, 2H), 7.73−7.68 (m, 1H), 7.64 (d, J =
5.4 Hz, 1H), 7.55 (t, J = 7.7 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.18 (d,
J = 5.4 Hz, 1H), 4.67 (t, J = 9.0 Hz, 2H), 4.37 (s, 2H), 4.32 (dd, J =
10.1, 4.9 Hz, 1H), 4.00 (s, 3H), 3.56 (d, J = 12.2 Hz, 3H), 3.46−3.42
(m, 4H), 3.32−3.19 (m, 2H), 3.11 (t, J = 7.1 Hz, 3H), 3.03 (t, J = 13.5
Hz, 3H), 2.35−2.25 (m, 2H), 1.92−1.81 (m, 3H), 1.80−1.69 (m, 1H),
1.60−1.46 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 173.03,
163.40, 158.76, 158.54, 156.44, 141.09, 139.18, 132.04, 131.95, 130.29,
130.07, 129.77, 129.37, 129.12, 127.76, 124.63, 120.11, 119.86, 115.45,




no-pentanoic Acid (12e). The standard reductive amination
procedure was carried out with 7b and 2-(piperidin-4-yl)acetonitrile
and then then Pbf removal to give a white solid, 6.4 mg, 19%. Rt 4.46
min. MS m/z −694.5 [M+ 1]+. HRMS (ES +ve): Calculated for
C33H40N7O6S2 694.2482. Measured mass 694.2455.
1H NMR (600
MHz, DMSO-d6) δ 10.06−10.01 (m, 1H), 8.27 (s, 1H), 7.69 (s, 1H),
7.64 (s, 1H), 7.53 (s, 1H), 7.46−7.33 (m, 3H), 7.28−7.08 (m, 3H),
4.60 (h, J = 8.9 Hz, 2H), 4.22 (s, 1H), 3.19 (t, J = 6.4 Hz, 3H), 2.85 (d,
J = 11.1 Hz, 2H), 2.54 (s, 1H), 1.98 (m, 1H), 1.75−1.64 (m, 2H).
(3-((5-(3-((Dimethylamino)methyl)phenyl)-2,3-dihydrobenzofur-
an)-7-sulfonamido)thiophene-2-carbonyl)-L-arginine (13a). Using
the standard method for reductive amination 1 × 0.12 mmol scale
reaction, the crude intermediate product was treated using the
standard conditions for Pbf removal. White solid, 21 mg, 0.025 mmol,
21% over 2 steps. LC-MS (pH 2): Rt 4.29 min. MS m/z −615 [M +
H]+. HRMS (ES +ve): Calculated for C28H33N6O6S2 613.1903.
Measured mass: 613.1912. 1H NMR (600 MHz, DMSO-d6) δ 10.08
(d, J = 7.6 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 7.60 (s, 1H), 7.54 (d, J =
1.9 Hz, 1H), 7.52−7.45 (m, 2H), 7.40 (t, J = 7.6 Hz, 1H), 7.27−7.23
(m, 1H), 7.23−7.17 (m, 2H), 6.81 (s, 2H), 4.60 (dq, J = 13.1, 8.8 Hz,
2H), 4.30−4.23 (m, 1H), 3.78 (d, J = 12.9 Hz, 1H), 3.71 (d, J = 12.9
Hz, 1H), 3.25−3.15 (m, 4H), 2.37 (s, 6H), 1.89−1.78 (m, 1H), 1.76−
1.60 (m, 3H). 13C NMR (151 MHz, DMSO) δ 175.01, 163.66, 163.13,
156.85, 155.95, 150.11, 139.85, 136.40, 131.38, 130.46, 128.97, 128.24,
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00210
J. Med. Chem. 2018, 61, 4135−4154
4149
127.31, 126.69, 125.59, 125.17, 125.06, 122.88, 114.15, 71.85, 61.71,
60.72, 52.17, 43.47, 28.83, 28.63, 25.29.
(3-((5-(2-(Aminomethyl)phenyl)-2,3-dihydrobenzofuran)-7-
sulfonamido)thiophene-2-carbonyl)-L-arginine (15a). The general
Suzuki method was used with 2-aminomethylboronic acid 1 × 3.6
mmol scale reaction. This gave 14a as a pale-yellow solid, 2.56 g, 3.2
mmol, 88%. Rt 3.31 min. MS m/z −812/814 [M + H]+. Standard Pbf
removal 1 × 0.12 mmol scale reaction. White solid, 48 mg, 0.057
mmol, 48%. Rt 2.37 min. MS m/z −839 [M + H]+. HRMS (ES +ve):
Calculated for C26H29N6O6S2 585.1590. Measured mass: 585.1590.
1H
NMR (600 MHz, DMSO-d6) δ 9.80 (d, J = 7.5 Hz, 1H), 8.30 (s, 1H),
7.92 (s, 1H), 7.61−7.56 (m, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.42−7.37
(m, 1H), 7.37−7.33 (m, 1H), 7.31 (d, J = 5.4 Hz, 1H), 7.22 (d, J = 5.4
Hz, 1H), 7.19−7.15 (m, 2H), 4.55 (dq, J = 30.7, 8.8 Hz, 2H), 4.15−
4.11 (m, 1H), 4.11 (d, J = 6.6 Hz, 0H), 3.94−3.82 (m, 2H), 3.17 (t, J =
8.8 Hz, 2H), 3.11 (s, 2H), 3.09 (s, 0H), 1.70 (d, J = 6.8 Hz, 1H), 1.53
(dq, J = 22.5, 7.7, 7.0 Hz, 3H). 13C NMR (151 MHz, DMSO) δ
175.52, 165.55, 162.92, 156.99, 155.49, 149.80, 140.98, 132.76, 130.76,
130.09, 129.67, 128.22, 127.94, 127.47, 127.39, 126.16, 123.51, 114.31,
71.76, 53.05, 29.81, 28.62, 25.30.
(3-((5-(3-(Aminomethyl)phenyl)-2,3-dihydrobenzofuran)-7-
sulfonamido)thiophene-2-carbonyl)-L-arginine (15b). The general
Suzuki method was used with 3-aminomethylboronic acid 3.6 mmol
scale reaction. This gave 14b as a pale-yellow solid, 2.56 g, 3.2 mmol,
88%. Rt 3.31 min. MS m/z −812/814 [M + H]+. Standard Pbf removal
1 × 0.12 mmol scale reaction, 1 × 0.062 mmol scale reaction. White
solid, 15 mg, 0.018 mmol, 29%. Rt 2.29 min. MS m/z −839 [M + H]+.
HRMS (ES +ve): Calculated for C26H29N6O6S2 585.1590. Measured
mass: 585.1610. 1H NMR (600 MHz, DMSO-d6) δ 9.97 (d, J = 8.6
Hz, 1H), 8.28 (s, 1H), 7.90 (s, 1H), 7.86 (d, J = 1.9 Hz, 1H), 7.82−
7.75 (m, 1H), 7.54−7.52 (m, 1H), 7.52 (d, J = 1.8 Hz, 1H), 7.38 (t, J =
7.7 Hz, 1H), 7.31 (d, J = 5.4 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.16
(d, J = 5.5 Hz, 1H), 4.63−4.50 (m, 2H), 4.28−4.16 (m, 1H), 4.03−
3.93 (m, 2H), 3.22−3.11 (m, 4H), 1.84−1.74 (m, 1H), 1.73−1.51 (m,
3H). 13C NMR (151 MHz, DMSO) δ 176.15, 164.85, 162.91, 161.15,
156.86, 155.97, 150.15, 139.95, 135.65, 131.34, 130.25, 129.06, 128.86,
127.23, 126.48, 126.08, 125.91, 125.55, 124.49, 123.33, 114.57, 71.64,







ester (5 g, 6.00 mmol), bispinacolato diboron (1.85 g, 7.3 mmol),
Pd(dppf)2Cl2 (443 mg, 0.6 mmol), and KOAc (1.78 g, 18.1 mmol)
were combined and suspended in dioxane (30 mL). The suspension
was degassed with nitrogen for 30 min before heating at 100 °C for 16
h. The reaction was allowed to cool to room temperature and
partitioned between EtOAc (200 mL) and water (200 mL). The
aqueous phase was extracted with EtOAc (2 × 100 mL), and the
combined organic extracts were washed with water (300 mL) then
brine (300 mL) and dried over Na2SO4. Concentration in vacuo
provided the crude product as a brown residue (6.6 g). The crude
product was puriﬁed by ﬂash column chromatography on silica gel
(eluent: neat ethyl acetate, increasing to ethyl acetate/MeOH 95:5),
aﬀording the desired product as a brown foam (3.73 g, 71%). Used
directly in the Suzuki reactions. LC-MS (pH 2): Rt 3.27 min. MS m/z
873 [M + H]+.
(3-((5-(Isoindolin-4-yl)-2,3-dihydrobenzofuran)-7-sulfonamido)-
thiophene-2-carbonyl)-L-arginine (18a). Following the general
Suzuki procedure but with CsCO3 as the base and 4-bromoisoindoline
used as coupling partner 0.34 mmol scale (single reaction), 120 °C, 10
min. This yielded 17a as a pale-pink solid, 128 mg, 0.15 mmol, 43%
(pH 2). Rt 2.38 min. MS m/z −865 [M + H]+. Hydrolysis of the
methyl ester and Pbf removal 0.15 mmol scale. Product white solid, 58
mg, 0.097 mmol, 65% (pH 2). Rt 4.25 min. MS m/z −599 [M + H]+
(pH 9). Rt 5.28 min; purity 99%. MS m/z −599 [M + H]+. HRMS (ES
+ve): Calculated for C25H26N5O6S2 597.1590. Measured mass:
597.1554. 1H NMR (600 MHz, DMSO-d6) δ 12.88 (s, 1H), 11.11
(s, 1H), 8.57 (d, J = 7.5 Hz, 1H), 7.75−7.71 (m, 1H), 7.69 (d, J = 5.5
Hz, 1H), 7.63 (d, J = 1.8 Hz, 1H), 7.52 (d, J = 1.8 Hz, 1H), 7.48 (t, J =
7.5 Hz, 1H), 7.44 (d, J = 7.0 Hz, 1H), 7.38 (dd, J = 7.5, 1.2 Hz, 1H),
7.21 (d, J = 5.4 Hz, 1H), 4.73−4.66 (m, 2H), 4.58 (m, 2H), 4.54 (m,
2H), 4.38−4.34 (m, 1H), 3.33−3.20 (m, 2H), 3.16−3.06 (m, 2H),
1.92−1.83 (m, 1H), 1.79−1.69 (m, 1H), 1.61−1.45 (m, 2H). 13C
NMR (151 MHz, DMSO) δ 173.14, 163.49, 156.79, 156.33, 141.36,
136.25, 135.13, 132.73, 132.01, 130.99, 129.30, 128.17, 126.00, 122.26,
119.90, 113.21, 73.86, 52.07, 50.35, 49.96, 40.32, 28.38, 27.34, 25.57.
(3-((5-(isoindolin-5-yl)-2,3-dihydrobenzofuran)-7-sulfonamido)-
thiophene-2-carbonyl)-L-arginine (18b). Using the standard Suzuki
procedure but with CsCO3 (3 equiv) as the base and boronic acid 16
following the Suzuki procedure used for 18a above and t-butyl-5-
bromoisoindoline-2-carboxylate as the coupling partners (scale 2 ×
0.11 mmol and 1 × 0.23 mmol − total scale = 0.46 mmol of boronic
acid). Product 17b white solid, 71 mg, 0.074 mmol, 16%. LC-MS (pH
2): Rt 3.40 min. MS m/z −965 [M + 1]+. Rt 3.46 min. MS m/z −951
[carboxylic acid + 1]+. Hydolysis of the methyl ester using LiOH
followed by standard Pbf removal. To a stirred solution of the methyl
ester (71 mg, 0.073 mmol) in THF (2.5 mL) was added 1 M lithium
hydroxide (aq, 0.37 mL, 0.36 mmol) and the reaction mixture stirred
at room temperature for 1.5 h. The solvent was removed in vacuo and
the residue dissolved in DCM/TFA (1:1, 1.8 mL) and stirred at room
temperature for 18 h and then 40 °C for 24 h. The solvent was
removed in vacuo and the crude residue dissolved in DMSO and
puriﬁed by (mass-directed) preparative LC-MS using a preparative C-
18 column (Phenomenex Luna C18 (2), 100 mm × 21.2 mm, 5 μM)
and a linear AB gradient of 5−95% for B over 12 min at a ﬂow rate of
20 mL/min, where eluent A was 0.1% formic acid/water and eluent B
was 0.1% formic acid/MeOH. The combined HPLC fractions were
concentrated in vacuo to provide the title compound as a white solid,
29 mg, 0.05 mmol, 66%. LC-MS (pH 2): Rt 4.03 min. MS m/z −599
[M + H]+. HRMS (ES +ve): Calculated for C25H26N5O6S2 597.1590.
Measured mass: 597.1576. 1H NMR (600 MHz, DMSO-d6) δ 12.88
(s, 1H), 11.08 (s, 1H), 8.71−8.35 (m, 1H), 7.80 (d, J = 1.8 Hz, 1H),
7.75−7.70 (m, 2H), 7.69−7.65 (m, 2H), 7.60 (dd, J = 7.9, 1.7 Hz,
1H), 7.48 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 5.5 Hz, 1H), 4.72−4.64 (m,
2H), 4.60−4.51 (m, 4H), 4.39−4.29 (m, 1H), 3.32−3.19 (m, 2H),
3.15−3.07 (m, 2H), 1.91−1.82 (m, 1H), 1.81−1.66 (m, 1H), 1.59−
1.46 (m, 2H). 13C NMR (151 MHz, DMSO) δ 173.15, 171.49, 163.48,
156.79, 156.58, 156.28, 141.36, 138.90, 136.25, 130.31, 126.67, 124.74,
123.58, 120.20, 119.88, 113.17, 73.79, 52.05, 40.32, 36.53, 28.37,
27.35, 22.55, 1.20.
Biology. United Kingdom: All in vivo study protocols, husbandry,
and anesthesia were performed by followed guidelines of United
Kingdom Home Oﬃce Scientiﬁc Procedures Act (1986). USA: All
animal work was approved by the Stony Brook University IACUC.
Protein Expression, Puriﬁcation, and Crystallization. Recombi-
nant human NRP1-b1 domain was expressed in Escherichia coli strain
Rosetta Gami 2 (DE3) pLysS cells. Gene sequence corresponding to
NRP1-b1 residues 273−427 was subcloned into pET15b vector,
resulting in a protein product that contains a TEV protease- cleavable
His6 tag on the N-terminus. The protein was puriﬁed to a high level of
homogeneity using a combination of Ni-NTA (GE Healthcare) aﬃnity
chromatography with size exclusion chromatography (Superdex S75,
GE Healthcare) and ion exchange chromatography using an SP FF
Sepharose column (GE Healthcare). Puriﬁed protein was dialyzed into
20 mM Tris-HCl pH 7.9 and 50 mM NaCl prior to crystallization.
Crystallization of both the high and low resolution crystals was
performed using the vapor diﬀusion methods using a 1:1 ratio of
protein to mother liquor. Crystallization of the low resolution
structure was carried out at 20 °C, with NRP1-b1 concentration of
10 mg/mL supplemented with 1 mM of 1 and with the precipitant
solution containing 16% w/v PEG3350 and 200 mM ammonium
chloride. Crystals of the high resolution structure were grown at 4 °C
with protein solution at 10 mg/mL supplemented with 2.3 mM of 1.
Crystallization condition contained 12% w/v PEG3350 and 200 mM
ammonium chloride. Prior to data collection, both crystals were
cryoprotected in mother liquor containing an additional 22% PEG300.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00210
J. Med. Chem. 2018, 61, 4135−4154
4150
Data Collection and Processing. Low resolution (2.8 Å) data was
collected at the Institute for Structural and Molecular Biology X-ray
crystallography facilities equipped with Rigaku Micromax 007
generator and a Rigaku Saturn 944+ CCD detector. The 600 images
were collected with a 0.5° oscillation which were processed using
d*TREK.38
High resolution (0.9 Å) data was obtained at Soleil, Paris.
Diﬀraction data was collected at the PROXIMA 1 beamline with a
DECTRIS PILATUS 6 M detector. The 1800 images of 0.1°
oscillations were collected and processed using XDS software.39
Molecular replacement was performed using Phaser40 with the
NRP1-b1 domain structure (PDB 3I97) as a model. Reﬁnement of the
lower resolution structure was performed using Phenix.41 The high
resolution structure was initially reﬁned with Phenix before completing
the reﬁnement using ShelXL.42 Model building of both structures was
performed using COOT.43 Data quality and reﬁnement statistics are
shown in Table S1 (Supporting Information).
SPR Experimental. Surface plasmon resonance experiments were
performed using a Biacore 4000 instrument at 25 °C. Sensor chips,
buﬀer stock solutions, and immobilization reagents were from GE
Healthcare. Recombinant human NRP1-b1 was as above. Other
reagents were obtained from Sigma. Immobilization: PBS (containing
0.05% surfactant P20) was used as the running buﬀer. The four ﬂow
cells were treated in the same way to optimize throughput. In
summary, using a CM5 chip spots 1 and 2 were activated with the
coupling reagents EDC and NHS for 10 min. NRP1-b1 at a
concentration of 20 μg/mL in 10 mM sodium acetate pH 5 was
injected onto the surface for 10 and 5 min in spots 1 and 2,
respectively, to generate surfaces with high and low density. The
immobilization levels ranged from 2302 to 1823 RU on spot 1 and
from 948 to 1112 RU in spot 2. The unmodiﬁed spot 3 was used as a
reference. Kinetics and aﬃnity measurements: PBS containing 0.05%
surfactant P20 and 3% DMSO was used as the running buﬀer and
sample dilution buﬀer. Dose−responses were obtained using a 2-fold
sample dilution from 16 μM to 31 nM, using an injection time of 60 s.
Surface regeneration between injections was not necessary, but a wash
step with 1 M NaCl was included after injection of the highest
concentration sample for each compound. Data processing: Binding
curves were corrected for variations in DMSO concentration and
normalized by molecular weight. Binding results to high and low-
density surfaces were processed independently and the average ± SD
is presented. KDs reported are derived from steady-state binding
responses and therefore correspond to the equilibrium binding aﬃnity
of the compounds.
Isothermal Titration Calorimetry. Isothermal titration calorimetry
(ITC) experiments were carried out in a reaction buﬀer (20 mM Tris
pH 7.9, 50 mM NaCl) using a MicroCal iTC200 system (Malvern) at
20 °C. Prior to the experiments, the Nrp1-b1 sample was dialyzed in
the reaction buﬀer and all solutions, including the buﬀer that was used
for heat dilution measurements, were degassed and ﬁltered just before
loading into the calorimeter. Then 20 μM Nrp1-b1 in the reaction cell
was titrated with the 200 μM stock solutions of 1. Nineteen
consecutive compound injections of 2 μL at 0.4 s/μL were applied at
100 s intervals while stirring the reaction solution at 1000 rpm
constant speed. For heat dilution of the protein, 0.2 mL of reaction
buﬀer in the reaction cell was titrated by 40 μL of 200 μM compound,
and this value was subtracted from the measured heats of binding.
Protein concentrations of the samples used in these experiments were
estimated by UV absorbance measurements at 280 nm. Data were
evaluated using Origin version 7.0 software (OriginLab) with the ITC
plug-in provided by the instrument manufacturer.
Pharmacokinetics. To test compound drug-like properties, selected
compounds with low IC50 were further tested for pharmacokinetics
(PK) proﬁle. First, 6−8 week-old BABL/c female mice were used,
then 2 mg/kg of compounds was formulated in 7.5% DMSO and
92.5% solution and intravenously dosed from the tail vein as a bolus.
Blood samples were collected by cardiac puncture at 5, 15, 30, 60, 180,
and 240 min post dosing. Plasma samples were prepared by
centrifugation at 7000 rpm for 5 min, and supernatants were collected,
immediately snap-frozen on dry ice, and stored at −20C. Samples were
analyzed by liquid chromatography−tandem mass spectrometry using
electrospray ionization and data was analyzed by WinNonlin software.
btVEGF-A Cell-Free Binding Assay. The 96-well plates were
precoated with NP1 protein at 3 μg/mL overnight at 4 °C. On the
following day, the plates were treated with blocking buﬀer (PBS
containing 1% BSA) and washed three times with wash buﬀer (PBS
containing 0.1% Tween-20). The various concentrations of com-
pounds diluted in PBS containing 1% DMSO were added, followed by
addition of 0.25 nM of bt-VEGF-A165. After 2 h of incubation at room
temperature, the plates were washed three times with wash buﬀer. The
bound bt-VEGF-A165 to NP-1 was detected by streptavidin−
horseradish peroxidase conjugates and the enzyme substrate, and
measured using a Tecan Genios plate reader at A450 nm with a
reference wavelength at A595 nm. Nonspeciﬁc binding was determined
in the absence of NP-1 coated wells of the plates.
Immunoblotting. Cells were lysed with RIPA buﬀer (Sigma)
supplemented with protease inhibitor (Roche) and phosphatase
inhibitors II and III (Sigma) and analyzed by SDS-PAGE with 4−
12% Bis·Tris gels (Nupage, Invitrogen), followed by electrotransfer
onto Invitrolon PVDF membranes (Invitrogen). Membranes were
blocked with nonfat dry milk (5% w/v) and Tween-20 (0.1% v/v) in
tris-buﬀered saline (TBS-T), for 1 h at room temperature before being
probed with the primary antibody by overnight incubation at 4 °C,
followed by incubation for 1 h at room temperature with a
horseradish-peroxidase-linked secondary antibody (Cell Signaling)
and detection with the aid of Clarity Western ECL Substrate
(BioRad), by the manufacturer’s protocol. Immunoblots were
quantiﬁed by scanning the ﬁlms and then performing densitometry
by use of ImageJ (US National Institutes of Health; http://rsb.info.
nih.gov/ij/). Diﬀerences between three concentrations of 1 were
evaluated by the two-way analysis of variance (ANOVA) with Sidak’s
multiple comparisons test. Values represent means ± SEM determined
from the results of three independent experiments. A value of p < 0.05
was considered statistically signiﬁcant.
Cell Culture. Human umbilical vein endothelial cells (HUVECs)
were obtained from TCS Cell Works (Buckingham, UK) and were
cultured on tissue culture-coated ﬂaks in endothelial basal medium
(EBM; Cambrex BioScience Ltd., Nottingham, UK) supplemented
with gentamycin−ampicillin, epidermal growth factor, and bovine
brain extract (Singlequots; Cambrex) and 10% fetal bovine serum
(FBS) (complete EBM). For experimental purposes, fully conﬂuent
HUVECs at passages 1−3 were preincubated overnight with 1% FBS
in EBM prior to addition of factors and other treatments. DU145/
cells.Ad.NRP1 cells: DU145 prostate cancer cells were from ATCC
and infected with an adenovirus expressing WT NRP1 as previously
described27 (cells were grown in 10% FCS in DMEM). A375P
melanoma cells were from ATCC. Cells were grown in 10% FCS in
DMEM.
Human dermal ﬁbroblasts (HDF) were obtained from TCS cells
Works Buckingham, UK) and were cultured in Dulbecco’s Modiﬁed
Eagle Medium (DMEM, Gibco) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (Gibco). For exper-
imental purposes, fully conﬂuent HDF at passages 1−3 were
preincubated overnight with serum-free DMEM prior to other
procedures. GL261 cells were purchased from ATCC and cultured
as described.44,45
Transwell Migration. Transwell cell culture inserts made of
transparent, low pore density polyethylene terephthalate (PET) with 8
μm pore size (Falcon; BD Biosciences, Oxford, UK) were inserted into
a 24-well plate. Serum-free media supplemented with or without 25
ng/mL VEGF-A, 0.1% DMSO, or 1 (30 μM) were placed in the
bottom chamber, and HUVECs in suspension (1.5 × 105 cell/well in
serum-free EBM) were added to the top chamber of a 24-well plate
and incubated at 37 °C for 4 h. HUVECs that had not migrated or had
only adhered to the upper side of the membrane were removed before
membranes were ﬁxed and stained with a Reastain Quik-Diﬀ kit (IBG
Immucor Ltd., West Sussex, UK) using the manufacturer’s protocols.
Plates were allowed to dry overnight and HUVECs that had migrated
to the lower side of the membrane were counted in three random
ﬁelds per well.
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Coculture. In vitro angiogenesis was determined by using a
coculture assay. Brieﬂy, HDF cells were grown to conﬂuence in 24-
well plates in 10% DMEM, 1% penicillin/streptomycin. Medium was
replaced, and 10000 HUVECs were plated on top of the ﬁbroblast
layer cultured in complete endothelial growth medium supplemented
with 1% FBS. HUVECs, or medium with 0.1% DMSO, VEGF 25 ng/
mL, 1 (30 μM), and 1 (30 μM) + VEGF 25 ng/mL and ﬁbroblasts
were propagated in coculture for 4 days at 37 °C and 5% CO2. Cells in
coculture were ﬁxed in absolute ethanol for 1 h at room temperature,
washed twice in PBS, and blocked using PBS 5% milk. HUVECs were
identiﬁed by incubating with anti-von Willebrand factor antibody
(Dako, 1:1000) in PBS 5% milk overnight at 4 °C. Antibody was
removed and cells washed with PBS. The secondary antibody, goat
anti-rabbit IgG, Alexa Fluor 488 conjugate (Life Technologies,
1:1000), was added on cells and left for 1 h in the dark. Solution
was removed and plate was scanned using IncuCyte.
Photomicrographs of von Willebrand factor-stained cocultures were
analyzed using ImageJ software. The Network area, length of all
tubular structures, and the number of branching points were measured
in four representative microscopic ﬁelds per well.
Scratch Assay. The experiment was performed using the ESSEN
IncuCyte system. Graduated 96-well plates from ESSEN were used to
seed HUVECs. When cells reached 95% conﬂuence, a wound was
made on every well using the Wound Maker 96 instrument (ESSEN
instruments). Wells were supplemented with 1% EGM containing
0.1% DMSO, 25 ng/mL VEGF-A, and/or 1 (30 μM). Cell migration
toward the wounds was monitored every 2 h and analyzed by the
IncuCyte software.
Ex Vivo Aortic Ring Sprouting Assay. This protocol was adapted
from previous studies.32 All animal and tissue procedures were carried
out in accordance with United Kingdom Home Oﬃce regulations and
guidance. Brieﬂy, female wild-type C57Bl/6 mice were killed in
accordance with United Kingdom Home Oﬃce regulations. Thoracic
aorta was harvested from aortic arch. Aorta was placed into a sterile
Petri dish containing Opti-MEM Glutamax (Life technologies) and 1%
penicillin/streptomycin. Under the dissection micrioscope, aortas were
cleaned by sharp dissection and the vessel sliced into 0.5 mm rings
with a scalpel. Rings were serum starved overnight at 37 °C in 5 mL of
OptiMEM Glutamax supplemented with 1% penicillin/streptomycin.
On ice, 1.37 mL of puriﬁed type 1 rat-tail collagen (Millipore, Watford,
United Kingdom) was mixed with 0.5 mL of 10× DMEM (Gibco) and
3.13 mL of dH2O before adding 2 μL/ml of 5 M NaOH. A 55 μL
amount of this embedding matrix was pipetted per well into a 96-well
plate and aortic ring submerged within. Plates were left for 15 min at
room temperature before incubation for 60 min at 37 °C. A 150 μL
amount of OptiMEM Glutamax containing 2.5% FBS and 1%
penicillin/streptomycin was added per well with medium containing
0.1% DMSO, 25 ng/mL VEGF-A, and/or 1 (30 μM). Aortic rings
were incubated at 37 °C for 7 days with a medium change on day 3
and 5. Wells were washed with 150 μL of PBS containing 2 mM CaCl2
and 2 mM MgCl2 and ﬁxed in 4% formalin for 30 min. The collagen
was permeabilized with three 15 min washes with PBS buﬀer
containing 2 mM MgCl2, 2 mM CaCl2, and 0.25% Triton X-100. Rings
were blocked in 30 μL of 1% BSA in PBLEC (PBS containing 100 μM
MnCl2, 1% Tween-20, 2 mM CaCl2, 2 mM MgCl2) for 30 min at 37
°C. Then 100 μL of a mix containing IsolectinB4 (1:100, Vector
Laboratories) and anti smooth muscle, SMA (1:100, Sigma) was
added per well, followed by overnight incubation at 4 °C. Wells were
washed three times with 100 μL of PBS containing 0.1% Triton X-100
and then with 100 μL of sterile water. Aortic rings were imaged and
the area of sprout growth was quantiﬁed using ImageJ software.
Spheroid Assay. Spheroids were generated using the metho-
cellulose technique as described previously. Brieﬂy, cells were
trypsinized and counted. A mix containing 10 mL of metho-
cellulose-containing medium (30% metho-cellulose, 70% culture
medium) was prepared and kept on ice. Approximately 5000 cells
were added to the mix. Spheroids were produced by pipetting 100 μL
of the cell suspension into a well of a 96-well round-bottomed
nontissue-culture plate and incubating for 24 h (37 °C, 5% CO2).
Spheroids were collected and embedded in a mix containing 700 μL of
collagen type I (3.1 mg/mL), 200 μL of 5× DMEM, 100 μL of H2O,
and supplemented with 0.1% DMSO, 25 ng/mL VEGF-A, and/or 1 30
μM. Spheroids were allowed to invade for 7 days, followed by ﬁxation
in 4% formaldehyde. Spheroid invasion was determined by measuring
the circular area of the spheroid core and the rim of invasion using
ImageJ. The rim of invasion was determined as the circular distance
from the edge of the core to the edge of contiguous invading cells.
Isolation and Treatment of Nrp1+ Regulatory T Cells. Primary
murine splenocytes were isolated from 6-week-old C57/Bl6 mice.
Brieﬂy, mice were heavily anesthetized with avertin (0.02 mg/g ip) and
perfused with 1× PBS. Spleens were dissected, chemically digested in
papain for 15 min at 37 °C, minced, and dissociated in PBS
supplemented with 1% FBS and 1 mM EDTA. Cell suspensions were
ﬁltered through 40 μm ﬁlters, washed thoroughly, and a Dynabeads
Untouched Mouse CD4 Cells kit (Invitrogen) was used to purify
CD4+ cells following the manufacturer’s protocol. The cells were then
puriﬁed further for Nrp1 expression using positive selection for Nrp1
using anti-Nrp1 antibody (Biolegend) and then using magnetic
Dynabeads (Invitrogen) to pull out this fraction. Cells were plated at a
density of 200000 cells per well. Plates were precoated with anti-CD3ε
(clone 145-2C11, BD Biosciences) overnight at 4 °C. Cells were
cultured in 250 μL of RPMI supplemented with 10%FBS, 1×
penicillin/streptomycin, and anti-CD28 antibody (clone 37.51, BD
Biosciences) for costimulation. Cells were allowed to expand for 72 h,
at which point they were treated with either DMSO control
(untreated) or 500 nM 1 for 2 h. Media was then supplemented
with 50% glioma-conditioned media (GCM) isolated from conﬂuent
plates of GL261 cells (ATCC)44,45 that were serum starved for 24 h.
Cultures were allowed to sit for 12 h, after which cells were isolated for
ﬂow cytometric analysis of CD4 (eBioscience), CD25 (Biolegend),
Nrp1 (Biolegend), and FOXP3 (BD Biosciences) expression using a
BD LSR Fortessa ﬂow cytometer (BD Biosciences). Medium was
isolated and TGFβ release by cells was quantiﬁed using a TGFβ Ready
Set Go ELISA kit (eBioscience) following the manufacturer’s protocol.
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